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ABSTRACT 
The pathogenesis of chronic inflammation, a common denominator in cardiovascular, 
metabolic and systemic autoimmune diseases, is influenced by a number of genetic, 
metabolic and immunological risk factors. Oxidation of cellular membranes and lipoproteins 
by reactive oxygen species generates a number of complex and distinct oxidized 
phospholipids (OxPL) thought to be involved in this pathogenesis. Since the discovery of 
OxLDL in atherosclerotic lesions, research on these oxidized phospholipids and protective 
factors/mechanisms has expanded in recent years. As a result, oxidized phospholipids and 
related antigens have been characterized extensively in connection not only with 
cardiovascular pathogenesis, but also with related diseases that also are associated with 
negative cardiovascular outcomes. As a consequence, these oxidized phospholipids are now 
known to play a key role not only in initiating inflammation, but also in mediating deleterious 
consequences.  
In our first study, we examined the potential pro-inflammatory features of oxidized 
cardiolipins, phospholipids present in LDL, where they might be exposed at the surface 
following oxidation. Initially, we determined whether oxidized cardiolipin (OxCL) exerts 
pro-inflammatory effects on macrophages and neutrophils and, if so, whether Annexin-A5 
can inhibit these effects.  As expected, OxCL induced leukotriene production by these 
immune cells in a calcium-dependent manner through activation of the 5-LOX gene. 
Moreover, Annexin A5 bound to oxidized, but not native cardiolipin, thereby abrogating both 
the elevated leukotriene production and even intracellular mobilization of calcium. Annexin 
A5 also inhibited the expression of adhesion molecules on endothelial cells and might thus 
play an important role in preventing the binding of lymphocytes and monocytes to these cells 
and resulting inflammation around atherosclerotic plaques.    
In our second investigation, we characterized the clinical significance of antibodies towards 
malondialdehyde, an important epitope exposed at the surface of both OxLDL and apoptotic 
cells, in 60-year-old patients with cardiovascular disease. An assay developed to measure 
circulating levels of anti-MDA IgMs revealed that these patients had lower levels than age- 
and gender-matched controls, especially the men (130.1 [107.8–155] versus 143 [120–165], 
p=0.001), RU/mL. The odds ratio and 95% CI below the 10th [2.0; 1.19-3.36] and above the 
66th percentile [0.68; 0.48-0.98] indicated that these antibodies can predict risk in such 
patients. Amino acid sequencing showed less variation in these antibodies than in non-
specific IgMs.    
  
To extend these findings to systemic autoimmune diseases, we next assessed the prevalence 
of anti-MDA and anti-PC IgM in patients with RA, SLE, SjS, SSc, MCTD, and UCTD. The 
levels of anti-PC, but not ant-MDA IgM were strikingly lower in the case of MCTD. 
Moreover, levels of both IgMs were low among those with SLE or Sjogren’s syndrome and 
high among patients with rheumatoid arthritis and primary phospholipid syndrome, with no 
difference in the case of UCTD. Furthermore, when anti-PC IgM was added exogenously, the 
number of immunosuppressive T cells (Tregs) increased, with no such effect with anti-MDA 
IgM. Finally, the amino acid sequences of these antibodies showed both certain similarities 
and differences. 
In our last study, we assessed the prevalence of anti–PC IgG1 and IgG2 in patients with SLE. 
Low levels of IgG1 proved to be indicators of risk, whereas higher concentrations were 
protective. In addition, exposure of macrophages to monoclonal antibodies against 
phosphorylcholine (developed in-house) improved the efficiency of phagocytosis by these 
cells in a manner dependent on complement, which might explain why higher levels of these 
antibodies in patients with SLE appear to be protective. 
Overall, the clinical and experimental evidence we provide here confirms the relevance of 
anti-PC and anti-MDA IgMs in connection with cardiovascular and autoimmune diseases. 
Both these natural protective antibodies and Annexin A5 could serve as prognostic markers 
and potentially be of value in treating inflammatory and autoimmune conditions. 
 
  
  
LIST OF SCIENTIFIC PAPERS 
I. Wan M, Hua X, Su J, Thiagarajan D, Frostegård AG, Haeggström JZ, 
Frostegård J. “Oxidized but not native Cardiolipin has pro-inflammatory 
effects which are inhibited by Annexin A5”. Atherosclerosis. 2014 
Aug;235(2):592-8. 
II. Thiagarajan D, Frostegård AG, Singh S, Rahman M, Liu A, Vikström 
M, Leander K, Gigante B, Hellenius ML, Zhang B, Zubarev RA, de Faire 
U, Lundström SL, Frostegård J. “Human IgM Antibodies to 
Malondialdehye conjugated with Albumin are Negatively Associated 
with cardiovascular Diseases among 60-Year-Olds”. Journal of American 
Heart Association. 2016, Dec 20;5(12).  
III. Thiagarajan D, Oparina N, Lundström S, Zubarev R, Sun J, the 
PRECISESADS Clinical Consortium, Marta Alarcon-Riquelme and 
Frostegård J, “IgM antibodies against malondialdehyde and 
phosphorylcholine in different rheumatic diseases”, Manuscript to be 
submitted.  
IV. Thiagarajan D, Frostegård A, Steen J, Rahman M, Vikström M, 
Zubarev R, Lundström S and Frostegård J, “IgG1 antibodies against 
phosphorylcholine are associated with protection in SLE and 
atherosclerosis: potential underlying mechanisms”. Manuscript to be 
submitted 
 
 
 
  
CONTENTS 
1 INTRODUCTION ......................................................................................................... 1 
1.1 Inflammation and immunity ................................................................................. 1 
1.2 Cardiovascular Disease and Atherosclerosis ....................................................... 2 
1.3 Inflammation in atherosclerosis ........................................................................... 3 
1.4 ROS and oxidation of lipids ................................................................................. 6 
1.4.1 Oxidized Low Density Lipoprotein ......................................................... 6 
1.4.2 Oxidized phospholipids and oxidation specific epitopes ........................ 7 
1.5 Protective factors to oxidized phospholipids in atherosclerosis ........................ 10 
1.5.1 Natural antibodies(Nab) ......................................................................... 12 
1.5.2 Annexin A5 ............................................................................................ 19 
1.6 Systemic Autoimmune Diseases and co-morbid CVD: .................................... 20 
1.6.1 SLE and CVD ........................................................................................ 20 
1.6.2 RA and CVD .......................................................................................... 22 
1.7 Therapeutics in CVD .......................................................................................... 22 
2 AIMS OF THE THESIS .............................................................................................. 27 
3 METHODOLOGICAL CONSIDERATION .............................................................. 29 
3.1 Patient cohort ...................................................................................................... 29 
3.1.1 60-Year-Old Cohort (Study II) .............................................................. 29 
3.1.2 PRECISESADS Cohort (Study III) ....................................................... 30 
3.1.3 The SLEVIC Cohort (Study IV) ............................................................ 30 
3.2 Clinical scoring ................................................................................................... 30 
3.2.1 CVD co-morbidity definition (Study III) .............................................. 30 
3.2.2 Carotid Ultrasound (Study IV) .............................................................. 31 
3.3 Enzyme Linked ImmunoSorbent Assay ............................................................ 31 
3.3.1 Biomarker measurement in cohorts (Study II, III and IV) .................... 31 
3.3.2 Monoclonal binding and competition assays (Study IV) ...................... 31 
3.4 Affinity purification of natural antibodies (Study II, III) .................................. 32 
3.5 Monoclonal production and gene sequencing (Study IV) ................................. 32 
3.6 De-novo sequencing using Mass spectrometry (Study II, III, and IV) ............. 33 
3.7 Cell culture ......................................................................................................... 33 
3.7.1 Primary cell culture ................................................................................ 33 
3.7.2 Cell Lines ............................................................................................... 33 
3.8 Phagocytosis assay (Study IV) ........................................................................... 34 
3.9 Gene expression analysis (Study I) .................................................................... 34 
3.10 Flow cytometry (Study I and IV): ...................................................................... 34 
3.11 Statistical analysis (All Studies): ....................................................................... 35 
4 RESULTS AND DISCUSSION .................................................................................. 36 
4.1 Oxidized but not native Cardiolipins is pro-inflammatory ................................ 36 
4.2 Annexin A5 binds to OxCL ............................................................................... 37 
4.3 Anti-MDA IgM and the risk for CVD ............................................................... 39 
  
4.4 Polyclonal anti-MDA IgMs differs from other IgMs ........................................ 39 
4.5 Antibodies against PC and MDA are different among different rheumatic 
diseases ............................................................................................................... 41 
4.6 Antibody levels and CVD comorbidity ............................................................. 43 
4.7 Antibodies influence regulatory T-cells in different fashions ........................... 44 
4.8 The peptide sequence of antibodies to phosphorylcholine and 
malondialdehyde are different ............................................................................ 45 
4.10 Dynamism among clonally selected antibodies ................................................. 47 
4.11 Anti-PC IgG1 improves the efficiency of phagocytosis by macrophages ........ 48 
5 GENERAL DISCUSSION .......................................................................................... 50 
6 CONCLUDING  REMARKS ..................................................................................... 53 
7 ACKNOWLEDGEMENTS ......................................................................................... 57 
8 REFERENCES ............................................................................................................. 61 
 
  
  
LIST OF ABBREVIATIONS 
CVD 
OxPL 
Cardiovascular Diseases 
Oxidized Phospholipids  
PC Phosphorylcholine 
MDA Malondialdehyde 
OxCL 
PtC 
PS 
4-HNE 
PUFA 
anti-PC 
anti-MDA 
ROS 
Oxidized Cardiolipin 
Phosphatidylcholine 
Phosphatidylserine 
4-hydroxy-2-nonenol 
Polyunsaturated Fatty acid 
antibodies against Phosphorylcholine 
antibodies against malondialdehyde 
Reactive Oxygen Species 
PAMP 
DAMP 
PRR 
OSE 
NAbs 
LDL 
HDL 
OxLDL 
IL6 
IL1b 
TNFa 
SLE 
RA 
MCTD 
UCTD 
SjS 
SSc 
Pathogen Associated Molecular Pattern 
Danger Associated Molecular Pattern 
Pattern Recognition Receptors 
Oxidation specific epitopes 
Natural Antibodies  
Low density Lipoprotein 
High Density lipoprotein 
Oxidized Low Density Lipoprotein 
Interleukin 6 
Interleukin 1 beta 
Tumor Necrosis Factor alpha 
Systemic Lupus Erythematosus 
Rheumatoid Arthritis 
Mixed Connective Tissue Disorder 
Undifferentiated Connective Tissue Disorder 
Systemic Sclerosis 
Sjogren’s Syndrome 
  
CD 
PAF 
IgM 
IgG 
LPS 
ELISA 
BSA 
HSA 
IMT 
NSAIDs 
DMRADs 
5-LOX 
COX-2 
VCAM-1 
ICAM-1 
HUVEC 
LTB4 
FURA-2AM 
CDR3 
POVPC 
PAF 
RU/mL 
Cluster of Differentiation 
Platelet Activation Factor 
Immunoglobulin M 
Immunoglobulin G 
Lipopolysaccharide 
Enzyme Linked Immunosorbent Assay 
Bovine Serum Albumin 
Human Serum Albumin 
Intima Media Thickness 
Nonsteroidal anti-inflammatory Drugs 
Disease Modifying Agents for Rheumatic Diseases 
5-Lipooxygenase 
Cyclooxygenase 2 
Vascular Cell Adhesion Molecule 1 
Intercellular Adhesion Molecule 1 
Human vein Endothelial cell 
Leukotriene B4 
FURA- 2 Acetoxymethyl ester  
Complementary Determining Region 3 
1-palmitoyl-2-(5’-oxo-valeroyl)-sn-glycero-3-phoshocholine 
Platelet Activating Factor 
Relative Units per milliliter 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  1 
1 INTRODUCTION 
1.1  INFLAMMATION AND IMMUNITY 
The concept of inflammation is defined as a response to external insult such as bacteria, virus, 
fungi or even toxins. Inflammation, has existed since ancient times when Greek associated 
heat and redness with diseases. Later, in the beginning of first century AD, Roman physician 
Celsus, identified Calor (heat), Rubor (redness), Dolor (pain) and Tumor (swelling) as 
cardinal signs of inflammation with Functio laesa (loss of function) being added later on by 
Galen1. Inflammation, is an innate response involving macrophages, dendritic cells, 
neutrophils and other immune that recognizes Pathogen- or Damage associate molecular 
pattern (PAMP/DAMP), via a series of specialized receptors called Pattern recognition 
receptors(PRRs)2.  
The family of PRRs includes both membrane bound Toll like receptors (TLRs), and C-type 
lectins and cytosolic NOD like receptors (NLRs)3. These recognizes not only conserved 
motifs in the pathogen such as flagellins, sugars and a number of cell wall components like 
lipopolysaccharide (LPS), peptidoglycan but also endogenous danger signals released from 
the injured or damaged cells, eg. dsDNA and uric acid crystals4. The recognition by the PRRs 
on macrophages and neutrophils stimulates the production of a range of cytokines such as 
TNF, IL1b, IL6 and certain chemokines to combat the initial insult. Neutrophils are the first 
cells to be recruited to site of inflammation, where they bind to the endothelial cells, secreting 
pro-inflammatory mediators like histamines and platelet activating factors (PAFs), that help 
in clearing the initial trigger. However, when the innate immunological response becomes 
inadequate and excessive, the adaptive system including T and B-lymphocytes is recruited for 
the clearance5.  
Although inflammation generally involves external antigen, this process is also essential for 
tissue repair and homeostasis6. Tissue damage often generates of lot of dead cells and cellular 
debris, as in case of necrotic cell death, that must be removed promptly and swiftly by innate 
immune cells resulting in sterile inflammation7. However, when the offending agent is not 
removed, and the inflammation remains unresolved, chronic inflammatory diseases develop 
with a variety of detrimental effect on the host including excessive release of reactive oxygen 
species (ROS). Cellular production of ROS affects a number of biomolecules, orchestrating a 
variety of inflammatory response, which involves phospholipids. In addition to being an 
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essential signalling molecule, ROS mediates inflammation and are thus implicated in a 
number of degenerative diseases such as atherosclerosis.  
1.2  CARDIOVASCULAR DISEASE AND ATHEROSCLEROSIS 
Cardiovascular diseases, a leading cause of mortality, affecting almost 17.9 million 
individuals, as of 2015 and accounting for 31% total deaths among CVD patients8. More than 
75% of these deaths occurred in the middle and low-income countries. Cardiovascular 
diseases include many different diseases associated with the heart and blood vessels: 
coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic 
heart diseases, congenital heart disease and deep vein thrombosis and pulmonary 
embolism.  
Among these, coronary heart disease and cerebrovascular complications account for 
approximately 85% of mortality worldwide, with atherosclerosis as the major underlying 
cause.  The word atherosclerosis means hardening of the arterial wall, derived from Greek 
word, (skelros = harden), through deposition of lipid containing immune cells with a porridge 
like consistency (athero means porridge-like) which begins as a simple fatty streak at a 
younger age and develops into advanced lesions at later stages of life. Atherosclerosis gives 
rise to these clinical consequences, through the formation of lesion, narrowing of arteries, 
plaque rupture and thrombosis, lead to acute coronary syndrome (ACS) where, myocardial 
infarction and stroke are the most common forms of cardiovascular disease.  
A number of traditional and non-traditional risk factors are involved in triggering the 
initiation and progression of atherosclerosis. The Framingham study, one of the largest 
epidemiological study in the field of cardiovascular diseases marked the important 
breakthrough in terms of assessing the associated risk factors9. Smoking, hypertension, 
family history, diabetes mellitus, male gender and old age were classified as classical risk 
factors of CVD10. In fact, the concept of cholesterol as proposed risk factor came from this 
study. People with family history of CVD and increasing age were more susceptible to 
cardiovascular events. The above factors contribute to increased production of ROS, from 
endothelial and smooth muscle cells, which leads to clinical consequences11. The 
involvement of cholesterol in triggering atherosclerosis, was demonstrated by Ignatowski and 
Anitschkow in pioneering studies, where rabbits were fed animal protein and fat rich diet12. 
Later, this conclusion was strengthened when Goldstein and Brown, discovered the LDL 
receptors, that regulates cholesterol metabolism, earning them the Nobel prize in 198513-16. 
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Later, Ridker and colleagues, proposed some novel risk factors including C-reactive protein, 
lipoprotein-A, homocystein and fibrinogen all related to coronary artery diseases17. 
1.3 INFLAMMATION IN ATHEROSCLEROSIS 
About 40 years ago, atherosclerosis was simply regarded as diseases resulting from lipid 
accumulation18-20. Its complexity lead to proposal of a number of theories attempting to 
explain the disease initiation and progression. Although, originally researchers based their 
models on the “Response to injury” theory, inflammation came later to regard as a key driver 
at all stages of the disease21-24.  
 
Figure 1: Distinct stages in the development of clinical atherosclerosis. Figure reprinted 
with permission25. 
Dysfunction of the endothelium is the hallmark of atherogenesis. Unlike smooth muscles 
cells or fibroblast, endothelial cells, grows in monolayers26 and are connected by tight 
morphological junctions, performing a plethora of functions ranging from acting as a barrier 
and performing  transport of molecules across the endothelium; vasodilation and contraction 
through secretion of nitric oxide (NO), provision of a surface to which lymphocytes do not 
adhere, and modification/oxidization of low density lipoprotein (LDL), which might cause 
endothelial dysfunction26, 27.  
Increased oxidative stress is proposed to be key factor in endothelial dysfunction28. The key 
factors responsible for endothelial activation includes: Oxidized low-density lipoprotein 
(OxLDL), mechanical injury, hypercholestremia, hypertension, smoking and genetic 
factors29.  The cellular damage is inflicted when ROS reacts with nitric oxide (NO), thereby 
promoting injury on endothelial and smooth muscle cells. This damage does not occur all 
over the artery, the hotspots being arterial bifurcation, leading to expression of the surface 
expression proteins VCAM-1 and ICAM-130. The adhesion molecule and chemo-attractants 
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such as MCP-1 released by endothelial cells facilitate the migration of lymphocytes and 
monocytes are also considered hallmark of atherosclerosis31. Upon migration, monocytes 
mature into macrophages which uptakes oxidized LDL, through their scavenger receptors 
CD36, SR-A1 and SR-B1. Excess uptake of OxLDL by macrophages eventually leads to 
formation of foam cell32.  Over time, the chronic accumulation of foam cells, ultimately leads 
to fatty streak, fibrous cap, complex plaque, thrombosis and clinical events as shown in figure 
1. 
Smooth muscles cells (SMCs) are present in both the fatty streak and fibrous cap of 
atherosclerotic lesion, with macrophages predominating the former and smooth muscle cells 
in the latter. The extent of proliferation of smooth muscle in the fibrous cap determines the 
future clinical outcome since such proliferation leads to connective tissue that can accumulate 
lipids33. In addition, SMC express receptors for LDL and secrete derivatives of prostaglandin 
that act as growth factors34-36. SMCs also respond to a number of chemoattractant protein, 
helping them to the migrate to intimal layers where they develop into the fibrous cap. 
Moreover, SMCs secretes collagen and apoptosis of SMC results in less collagen and 
vulnerable plaque. The SMCs migrate from tunica media to intima, by degrading the 
extracellular matrix with the help of matrix metalloproteases (MMPs)37. Also, CD40L 
produced by platelets plays an important role in this phase of disease38. Eventually, the 
platelets elicit atherogenesis by adhering to a dysfunctional endothelial monolayer. They are 
known for their chemotactic and mitogenic properties secreting platelet derived growth factor 
(PDGF)39 and epidermal growth factor (EGF)40, that promote migration and proliferation of 
SMCs40, 41. Moreover, for these mitogens in fibroblast and monocytes are responsible for 
chemotactic activity of the monocytes42.  
A seminal publication by Jonasson and colleagues revealed abundant expression of HLA-DR 
in plaques, suggesting that involvement of inflammatory reactions43. Later through thorough 
investigation of plaque tissue, this same group, showed CD4+ as well as CD8+ T cells, few 
or no B-cell and lack of neutrophils, indicative of chronic inflammatory stage44. 
Subsequently, this finding and field of inflammation induced atherosclerosis was supported 
by the research of Peter Libby and others21-24, 45. However, this is not such a new concept, 
since immunological dominance was proposed to cause arterial injury by Rudolf Virchow 
and French in the 1860’s 46, 47. Indeed, Rudolf Virchow was the first to identify the 
inflammatory nature of the atherosclerosis describing diapedesis of lymphocytes on vessel 
wall 47.  
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Figure 2: Inflammatory cascade leading to plaque rupture. Figure reprinted with 
permission48. a) Normal vessel structure showing tunica intima, media and adventitia, 
endothelial and SMC b) Adhesion and migration of monocytes and leucocytes into the 
vessel wall, c) Migration of SMC to intima leading to accumulation of apoptotic bodies, 
foam cells, cholesterol crystal and collagen and d) Thrombus formation and rupture of 
plaque leading to clinical consequences. 
As mentioned above, excess uptake of OxLDL by macrophages eventually leads to formation 
of foam cell. Progressive accumulation of these cells leads to fatty streaks, atherosclerotic 
lesions and fibrous cap formation. At the same time, T cells, predominantly pro-inflammatory 
T cells (Th1) migrate into the subendothelial space a phenomenon also observed in 
connection with other autoimmune diseases such as RA49. Moreover, excessive production of 
the pro-atherogenic cytokines TNF-a, IL 6, IL 1b, and IL 17 were observed in atherosclerotic 
plaques. Formation of new blood vessels causing hemorrhage within plaques leads to 
thrombin formation, which in turn causes activation of endothelium and leucocytes. Now, in 
this stage we can see active involvement of endothelial cells and immune cells like 
macrophages and T-cells, SMCs thus suggesting a synergistic relation between inflammation 
and thrombosis 50.  
The rupture of plaque is due to local inflammation in the plaque rather than the degree of 
stenosis itself 21. The ruptured plaque usually consists of abundant macrophages and MMPs 
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which facilitate dysregulation of extracellular matrix causing plaque rupture 51. This is due 
the physical disruption of the fibrous cap which causes the lipid containing thrombogenic 
core to get exposed to blood as shown in figure 2.   
1.4 ROS AND OXIDATION OF LIPIDS 
Utilization of oxygen is required for a number of physiological and metabolic process such as 
energy production, biosynthesis of cellular components associated with production of reactive 
oxygen species. Low levels of ROS are important for fighting infection but imbalanced 
production can lead to irreversible damage to DNA, lipids and protein and even cell death52. 
When this is process is unresolved, the process in-turn leads to release of free-radicals, which 
further promotes the oxidation. The biomolecules that are most affected by ROS includes 
lipids52-54, specifically phospholipids that are abundant in the plasma membrane, cell 
organelles like mitochondria and also oxidized LDL. NADPH oxidase, Nox-2 and Nox-4 and 
mitochondria are powerful source of ROS in the endothelium55. Oxidation of Polyunsaturated 
Fatty acids(PUFA)56-58 often referred as lipid peroxidation, produces a number of reactive and 
degradation products derived from the self. Often these degradation products, which are 
modified from the self, are known as oxidation specific epitopes(OSE) and are recognized by 
PRRs59 are known to trigger inflammation. These OSEs play an important role in  
atherosclerosis, where, their exposure both on apoptotic cells and  OxLDL plays a vital role 
in the pathogenesis29.  
1.4.1 Oxidized Low Density Lipoprotein 
Convincing evidence from the group of Cleveland clinicians, showed oxidation was key 
process in converting LDL to OxLDL that render cytotoxic effect60. Later, Steinbercher and 
colleagues, in their interesting paper, proposed endothelial cell cells modifies LDL through 
peroxidation process27. OxLDL, as such is a complex biological compound, that contains 
about 700 different phospholipids, 600 molecules of free cholesterol, 1600 molecule of 
cholesterol ester and 185 different triglycerides and one molecule of apolipoprotein B-100 
(apoB) as shown in figure 3. The extent of the phospholipid exposure at the surface of 
OxLDL, depends on the degree of oxidation61. Since oxidized LDL is the central molecule in 
the pathogenesis of atherosclerosis, a deeper understanding of the individual components, 
specially phospholipids are absolute necessary as they are prone to oxidation and recognized 
by immune cells.  
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Figure 3: Structure of OxLDL exposing different components: phospholipids, 
triglycerides, apolipoprotein and cholesterol. 
 
1.4.2 Oxidized phospholipids and oxidation specific epitopes 
Through enzymatic and non-enzymatic mechanisms involving lipoxygenases, 
cyclooxygenases and free radicals, immensely facilitates oxidation of PUFAs in the 
biological membrane and the cytosol57, 62.  Phosphatidylcholine(PtC), the most abundant 
phospholipid in both cell membrane and low-density lipoprotein results in production of a 
number of degradation which includes: phosphorylcholine-oxidized phospholipids (PC-
OxPL), oxidized cardiolipin (OxCL), oxidized phosphatidylserine (Ox-PS), and highly 
reactive aldehyde called malondialdehyde (MDA) and 4-HNE, as shown in figure 4. All these 
oxidized phospholipids are endogenous triggers classified as Danger Associated Molecular 
Pattern (DAMP) recognized by both membrane bound and soluble Pattern recognition 
receptors of the innate immune system. This finding suggested that specific oxidized epitopes 
are dominant targets of innate immune cells with a focus on certain phospholipids in the 
context of atherosclerosis. Pertinent to this, OSEs also contribute to other inflammatory 
conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), diabetes 
and cancer63. These phospholipids especially the protective factors against them, such as 
natural antibodies and Annexin A5 are primary focus here in this thesis.  
 
 
Apoprotein
Phospholipids
Unesterified
cholesterol
Triglycerids
Free
cholesterol
 8 
 
Figure 4: Schematic illustration of Phospholipid oxidation due to oxidative stress. 
Reprinted with permission64.  
 Phosphorylcholine (PC) 
The well characterized oxidation specific epitope (OSE) of phosphorylcholine has a unique 
structure that act as molecular mimic of both oxidized phospholipids and microbial antigens. 
It was first discovered in 1967 by Tomaz, is attached to polysaccharides in Gram-positive 
bacteria Streptococcus pneumoniae65. This epitope is also present in an array of other species 
of bacteria including, Clostridium spp.66, Lactococcus spp.67 and Bacillus spp67. of gram-
positive bacteria. Oxidized phosphorylcholine is also abundant in filarial nematodes, and its’s 
immunomodulatory effect has been extensively studied68.  
Oxidized phosphorylcholine is a dominant epitope implicated in the development of 
atherosclerosis and certain other chronic inflammatory diseases69. Though not exposed under 
normal physiological conditions, phosphorylcholine is an integral component of the most 
abundant phospholipid phosphatidylcholine (PtC), thus helping to maintain cell structure and 
integrity. In addition, this phospholipid is an integral part of low density lipoproteins (LDL) 
oxidation of which causes conformational changes exposing PC70. PtC contains one saturated 
and one unsaturated fatty acid. During inflammation, due to excessive ROS production and 
consequent oxidation at the Sn2 position, phosphorylcholine is exposed at the outer leaflet 
and becomes the immune dominant epitope in oxidized LDL and apoptotic cells which 
contain a great deal of PC, undergo this same modification to be identified by natural 
antibodies71. Phosphorylcholine is also an integral part of inflammatory mediator platelet 
activating factor (PAF) and other phospholipids such as sphingomyelin 72 . 
 Malondialdehyde (MDA) 
MDA, a reactive aldehyde, is another important end-product of the lipid peroxidation and 
serve as the most commonly utilized marker of this process73. In-vivo, most MDA is 
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produced by oxidation of PUFA, containing two or more double bonds interrupted by 
methylene moiety. As proposed by Del Rio, as reviewed in74, where MDA is the end product 
of peroxidation of either methyl linoleate, acrolein or prostaglandin. Physiologically, MDA 
epitope is predominantly found micro-vesicles, apoptotic cells, low density lipoprotein 
(LDL), high density lipoprotein (HDL), surfactants proteins and cartilage collagen75. 
Importantly, MDA forms adduct with histone on DNA, leading to mutations and eventually 
certain forms of cancer. Unlike PC, MDA is studied for its pathogenic properties that affects 
many cells types such as: macrophages, lymphocytes, endothelial and epithelial, causing 
apoptosis and production of pro-inflammatory cytokines75.  Clinically, in addition to MDA 
has been linked to several types of cancers76-80, Diabetes mellitus81 and pre-eclempsia82, 83 as 
well as in CVD.  
Oxidative modification of LDL is one of the best characterized in terms cholesterol 
accumulation by macrophage, where MDA plays a crucial role. Immuno-histochemical 
identification of atherosclerotic lesion of rabbits84. Extraction of LDL from human lesion 
confirmed presence of MDA epitopes85. This observation followed a series of studies, where 
immunization with in-vitro MDA modified LDL, lessened atherosclerotic lesion, indicating 
existence of protective response against them86-88. Alteration of LDL by MDA lead to 
cholesterol accumulation by human macrophages89. MDA forms adduct with amino group to 
form the Nɛ-(2-propenal) lysine and generate lysine–lysine cross-links via 1-amino-3-
iminopropene. Another potential toxic mechanism involves cross-inking of collagen, which 
in turn affects cardiovascular tissue90. A recent publication pointed out that in coronary 
tissues DNA methylation mediates MDA toxicity through the AKT-FGF2 pathway 91.  
 Oxidized Cardiolipin (OxCL) 
The lipid cardiolipin (CL) has a unique structure containing two phosphatidyl groups bridged 
by a glycerol group. CL has two negative charges and four18-carbon fatty alkyl chains of 
which two are unsaturated fatty acids. This lipid is localized to membranes, where electron 
transport and phosphorylation common e.g., the inner mitochondria and bacterial cell 
membranes. Cardiolipin is an integral part of LDL, and oxidation the unsaturated fatty acids 
forms OxCL, which plays a role in Cardiovascular diseases. Important functions of 
cardiolipins include triggering apoptosis, serving as proton trap for oxidative 
phosphorylation, and regulating aggregated structures.  
The structure of the above mentioned phospholipids are illustrated in the figure below. 
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Figure 5: The structure of Oxidation specific epitopes: a) POVPC and PtC exposing 
Phosphorylcholine, b) Malondialdehyde and c) Cardiolipin. 
 
1.5  PROTECTIVE FACTORS TO OXIDIZED PHOSPHOLIPIDS IN 
ATHEROSCLEROSIS 
Oxidation specific epitopes play important roles in both physiological and pathological 
processes.  As described earlier, OSE exposed at the cell surface present in biomolecules: and 
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when oxidized innate immune cells promptly remove them, thus maintaining normal 
homeostasis functions and tissue turnover. However, under pathological conditions, this 
homeostasis is disturbed due to the enormous burden associated with inflammation of the 
continuous oxidation reaction, and consequent inefficient clearance of apoptotic cells. This 
sensing and removal of OSE is facilitated by a broad range of pattern recognition receptors 
(PRR) both cellular and soluble expressed by the innate arm of the immune system. 
Scavenger receptors and toll-like receptors constitute most of the cellular PRRs that 
recognizes oxidation specific epitopes. The scavenger receptors include: CD36, SR-A1 and 
SR-B1, LOX-1, CD68 predominantly found on macrophages 92, 93. CD36, SR-A1 and SR-B1 
are essential for the uptake of OxLDL by macrophages and silencing these receptors reduces 
this uptake by at least 70-80%94. Initially, these receptors as well as (SR-A1 and SR-B1) were 
characterized with respect to their ability to recognize PC-OxPL95, 96, but they were later also 
found to bind to MDA-modified protein and 4-HNE97, 98. Similar to the scavenger receptors, 
TLRs also play a crucial role in sensing OSEs.  
PC-OxPL, again has been one of the important targets of the TLRs, with E06 IgM inhibiting, 
IL6 secretion by the OxPAPC (which has PC epitopes exposed), but not LPS99. On the other 
hand, uptake of OxLDL, requires effective co-ordination with CD36, which requires CD36, 
for its recognition100. However, MDA and 4-HNE do not directly elicit production of any 
chemokines, which implies that other PRR might be involved in their recognition.  
Often considered to be the marker of the acute phase protein in inflammation, CRP 
recognizes molecular patterns in both the pathogens and altered endogenous compounds, first 
identified during Streptococcus infection. Later, recognition was found to involve a common 
ligand, PC-OxPL found in them101. However, their ability to bind to MDA-LDL has not yet 
been examined.  The role of complement proteins was studied initially in mice with Ldlr 
deficient animals, deficient in C3 complement leads to development of atherosclerosis102. 
Both C3 and terminal complement complexes(C5b–C9) can be detected in atherosclerotic 
lesions103. The figure demonstrating the recognition of oxidation specific epitopes and 
phospholipids by innate immune cells is shown below. 
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Figure 6: Soluble and membrane PRRs recognizes oxidation specific epitopes. 
Reprinted with permission104. 
 
1.5.1 Natural antibodies(Nab) 
Although natural antibodies were probably first originated approximately 50 years ago in the 
late 19th century, Paul Ehrlich, proposed “horror autotoxicus”105, i.e., autoantibodies that 
reacts with self-structures and are mostly involved in pathological process. Much later in 
1991, Stratis Avrameas, proposed the term “Gnothi seauton” a term referring to repertoires of  
natural antibodies required for the self- structures are required for general homeostasis of the 
organism106. 
For many years these antibodies were regarded as insignificant but around mid 1920’s 
evidence of their functions association with bacteria started to emerge107 and 10 years later, 
Kidd and Friendewald, pointed out their functional specificity towards normal tissue 
constituents108 opening a new field of these protective natural IgMs act in co-ordination with 
complement proteins to perform their innate functions109. 
Although, the IgM subclass has been most extensively studied, recent evidence indicates 
natural IgG antibody, mostly IgG3 subclass participate in certain innate functions in a manner 
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not completely understood. Purified natural IgG binds to sugar residue on gram-positive and 
gram-negative bacteria and specifically associate with ficolins to make uptake of bacterial 
more effective110. They also known to interact with CRP111, TLRs112, 113 and C1q113. Their 
potential protective function against chronic inflammatory conditions such as SLE or 
atherosclerosis is of considerable interest. 
Phenotypically, circulating natural antibodies are IgMs, IgGs and IgAs and are poly-reactive 
in both humans114 and in mice115 recognizing antigens from endogenous as well as exogenous 
sources. Site-directed mutagenesis in mice revealed that CDR3 region is responsible for this 
poly-reactivity.116, 117 By ELISA techniques these antibodies have been shown to bind both 
intracellular and circulating including thyroglobulin, cytoplasmic antigens in polynuclear 
neutrophils, intrinsic factor, Factor VIII (FVIII), anionic phospholipids and glomerular 
basement membrane118, 119, which are also important targets in connection with autoimmune 
diseases. However, these antibodies differ from their pathological counterparts exhibiting fine 
specificity120.  
 B1 cells - producers of protective natural antibodies 
Plasma B cells produce Immunoglobulins(Igs) of five subtypes: IgA, IgD, IgE, IgG and IgM, 
characterized on the basis of the constant region. IgMs are the first subclass produced prior to 
class switching to effectively eliminate infection and maintain immune homeostasis. After 
contact with the antigen, IgMs class switch to one of the other four subtypes. IgGs are most 
prevalent class in the circulation and mucous. These antibodies function by activating 
complement, neutralizing antigen, priming immune cells and phagocytosing apoptotic cells. 
In addition of a unique subclass of antibodies called “natural antibody” is produced in both 
humans and in mice prior to infection.  
While T-cells contribute to cellular immunity, B-cells produce antibodies to specific antigen, 
thus participating in humoral arm of the adaptive immunity. B cells are divided into two 
different subtypes, B1 and B2 cells. B2 -B cells, located in the follicular and marginal zone 
produce antibodies against foreign antigens, whereas B1 B-cells produce antibodies against 
self-antigens and can self-replenish. Although, B1 cells predominantly produce IgMs (about 
80%), they also generate IgG and IgA.121, 122.  
Most of the functional studies related to B1 cells have been performed in mice. B1 cells were 
first identified among the CD5+ population, which is associated with autoimmune disease 123. 
B1 cells are divided into B1-a cells that express CD5 whereas B1-b cells on their surface and 
B1-a that do not. Although these cells share many similar properties, B1-a cells are more 
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often are self-replenishing in association with autoimmune conditions, while self-replenishing 
B1-b cells can also develop from progenitor cells from bone marrow 124-126. B1-a cells appear 
in the mouse embryo as early as 8.3 days post fertilization 127 mostly in the peritoneal and 
pleural cavities128. However, the mechanism by which they generate autoantibodies of these 
antibodies class is still not well understood. The B1-cells are encoded in the germ-line and 
not mutated in their VH and VL regions 129.  
Moreover, B1 cells can be subject to positive selection in the presence of self-antigens as 
shown by Hayakawa and co-workers utilizing transgenic mice and antigen recognition 
through B-cell receptors (BCRs) is essential for their development130-132. In this classical 
paper, they demonstrated the importance of BCR and their activation, by crossing B1 cells 
producing anti T-cell antibodies with the Thy-1-/- strain, in which B1-cells were unable to 
produce such antibodies130, 132. In addition, B1 cells interact weakly perhaps due to their 
inability to enter into the germinal centre to mature into high affinity autoreactive pathogenic 
cells. The B1-cells cells produce antibodies that bind not only oxidized phospholipids and 
certain self-antigens expressed on apoptotic cells but also lipids present in the cell wall of 
gram-positive bacteria such as Pneumococcus, thus protecting against atherosclerosis in 
several ways133. Antibodies produced by B1 cells are poly-specific and have low affinity for 
many different antigens. 
Until recently, the existence of human B1 cells are a huge topic of controversy. Although 
quite challenging, Griffin and colleagues identified CD20+CD27+CD43+CD70- in umbilical 
cord blood and peripheral blood cells of humans134. Furthermore, these number of these 
memory B1 cells decline with age perhaps explaining why the old people are more 
susceptible to cardiovascular problems and chronic infection. Although the B1-cells of mice 
produce antibodies in a T cell-independent manner encoded in the germ-line, protective 
autoantibody production in humans was recently shown to be hugely dependent on T-cells135.  
Approximately 50% of IgMs from human umbilical cord are autoreactive towards apoptotic 
cells and specifically reactive towards Cu-OxLDL and proteins modified by MDA as in 
mice71.  Gene sequencing of the complementary determining region, CDR region of B1 cells 
isolated from healthy human showed somatic hyper-mutations, revealing that these antibodies 
are products of affinity maturation 136. Although on the basis of microarrays of Merbl and 
colleagues claimed that (B1-derived) antibodies in new-borns bind almost 305 self-antigens 
137. ELISA measurements revealed, showed little or absent natural anti-phosphorylcholine 
antibodies in the serum of new-borns but presence of anti-malondialdehyde IgM138, 139. 
Antibodies against PC are well characterized and the relevance of antibodies against other 
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products of oxidation like MDA, CL and PS is starting to emerge. These antibodies produced 
by B1-b-cells differing in phenotype and mutation from their mice counterparts. 
 Function of natural antibodies 
The function of natural antibodies depends on their signalling threshold with respect to the 
encountered antigen140. Natural antibodies were initially characterized in terms of their 
adaptive functions, but are now extensively studied for their innate properties. These T-
independent antibodies in a genetically controlled manner119, 141, 142 are produced by 5-15%119 
splenic B cells 20% of which are autoreactive143. 
1.5.1.2.1 Athero-protective natural antibodies 
As indicated above low-density lipoproteins (LDL) play a central role in the pathogenesis of 
atherosclerosis. Oxidation of LDL results in the formation of neo-epitopes on both lipid and 
protein molecules144 forming adducts with phosphorylcholine and malondialdehyde 
headgroups, that are detected by cells of both the innate and the adaptive immune system145. 
The ability of natural antibodies to bind oxidation specific epitopes (specifically lipids) has 
led to investigation of their prevalence in patients with cardiovascular disease and systemic 
inflammatory diseases associated with increased cardiovascular risk such as SLE.  
Natural antibodies bind to one or more epitopes on OxLDL and prevent their uptake by 
macrophages, thus preventing/slowing the formation of foam cells146, 147. Immunization of 
mice with LDL modified with MDA or pneumococcus increases production of athero-
protective anti-MDA IgM and anti-PC IgM, respectively in mice148, 149. These antibodies do 
not bind to native or non-oxidized phospholipids not even though those containing the same 
phosphorylcholine head group. These antibodies block uptake of OxLDL by macrophages, 
eventually reducing plaque formation150.  
Natural antibodies against PC-OxPS are among the most well characterized of their ability to 
recognize both pathogen and endogenous danger. Having been studied extensively in the 
1970’s and 80’s they were initially identified as the TI5 idiotype providing protection 
function against streptococcal infection in mice151. The clones were given names TEPC-15 
and M167 and found reacting to small hapten “phosphorylcholine”152. Most of the 
immunological and functional properties of these antibodies, such as genetic sequence, germ 
line encoding and class switching was validated during this same era. About 20 years later, 
IgM antibodies generated from naive ApoE-/- mice 150 were termed “E0” and found to be 
structurally and functionally related to the T15 idiotype that binds phosphorylcholine-
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containing OxLDL147, 150. Nishinarita and Sawada, determined the concentration of anti-PC 
IgG and IgM in normal human serum to be 320 and 110 µg/mL respectively153. 
Several epidemiological studies performed by our group and others pointed out that high 
titres of antibodies against these lipid antigens are associated with protection against 
cardiovascular disease 154-162. The levels of anti-PC antibodies among healthy individuals 
differed 100-fold and were correlated with CRP levels 163. In fact, CRP and anti-PC IgM 
compete for same epitope, phosphorylcholine101. Furthermore, anti-PC IgM levels were 
higher among women than men 155 and found to decrease with age164. 
Among hypertensive patients those with high level of anti-PC exhibited low intima media 
thickness (IMT) progression, a hallmark of carotid atherosclerosis 155. Interestingly, the anti-
PC IgM level in serum of the Kitava population in New Guinea (with a low incidence of 
cardiovascular disease) are significantly higher than in age- and sex-matched Swedish 
controls160. Individual serological analysis of 60-year-old Swedish patients with CVD (both 
men and women) confirmed that a lower titre of IgM antibodies against phosphorylcholine 
and malondialdehyde are independent predictors of the risk for progression 69, 165. In addition 
to the level antibodies against OxLDL in human sera is inversely proportional to the 
development of carotid atherosclerosis 166. 
Protection by anti-PC IgMs is not only observed in the case of atherosclerosis but also with 
other chronic inflammatory diseases with cardiovascular risk such as SLE 156, 158. Thus, low 
level of anti-PC antibodies in SLE patients is associated with increased the cardiovascular 
risk 157, 167 as well as elevated risk for stroke 162. Earlier studies in mice showed that natural 
antibodies inhibit the development of inflammatory arthritis 168. In line with this finding, anti-
TNF therapy in patients with RA improved enhances serum anti-PC levels169. In addition the 
level of these antibodies predicts Alzheimer’s disease170. All of these observations indicate 
that circulating anti-PC antibodies regulates several chronic inflammatory diseases. 
Much of the protective effects against MDA-LDL was studied in animal models. Initial 
studies on mice, suggested these monoclonal antibodies against MDA recognize Oxidation 
specific epitopes in OxLDL86-88, 102. A study lead by Chou and colleagues, proposed MDA-
modified LDL are the most dominant targets among other oxidation specific epitopes, in 
germ-free conditions that are recognized by innate immune cells, for example, natural 
antibody71. The same group, generated a monoclonal antibody against MDA-LDL, originated 
in spleen, recognizing both OxLDL, and apoptotic cells, specifically later apoptotic cells. 
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Even stimulation of B1 cells in-vitro generates antibody against MDA-LDL, in the same mice 
model, reviewed by Weismann104.  
The studies on human came much later, where mostly associations were done with MDA-
LDL, but not with respect to anti-MDA IgMs. Although, Tsimikas and colleagues, in a 
longitudinal 15-year study, showed MDA-LDL was associated with lower risk in patients 
with CVD and stroke outcomes171, rather extensive studies in the previous years were made 
with respect to OxLDL155, 172, 173. More studies focusing on IgMs against MDA-LDL are 
starting to emerge. In addition, the fab fragment of antibodies bound to atherosclerotic 
plaques and the antibodies also recognize microbial antigens of Porphyromonas gingivalis174. 
But in contrast, these antibodies of IgG1 subclass promote the pathogenesis of RA175. Unlike 
PC IgMs, IgMs MDA modified proteins is not well established with respect to different 
cardiovascular outcomes, deserves deeper understanding. 
 Other functions of natural antibodies associated with athero-protection 
1.5.1.3.1 Protection against Infection 
Since these antibodies have a broad specificity, they recognize a variety of bacterial and viral 
antigens including non-protein carbohydrate and lipid moieties. Anti-PC antibodies bind to 
PC in the cell wall of Streptococcus pneumoniae 176 and protect against pneumococcal 
infection both in mice and also in humans. Recently, low levels of anti-PC and anti-MDA 
antibodies among patients with HIV patients were found to be low 177. In fact, vaccinating 
mice with pneumococcus found to reduce atherosclerotic lesion149. 
1.5.1.3.2 Promoting efficient phagocytosis of apoptotic cells 
Everyday approximately hundred billion senescent cells die undergo apoptosis in order to 
maintain normal tissue homeostasis 178. If not swiftly removed, these cells become necrotic, 
releasing cellular contents like dsDNA, HMGB-1 (High mobility group box-1) or HSP (heat 
shock protein) that can provoke an inflammatory immune response. One of the most 
important homeostatic functions of innate immune cells is to recognize the “eat-me” signals 
exposed on apoptotic cell surfaces and clear these cells efficiently179, 180.  
When a cell undergoes apoptosis, it expresses several neo-epitopes recognized by innate 
immune cells such as macrophages and dendritic cells71, 181. Moreover, natural antibodies aid 
in the recognizing of certain oxidation-specific epitopes (OSE) expressed specifically on the 
surface of apoptotic or stressed cells including phosphorylcholine (PC), malondialdehyde 
(MDA), phosphatidylserine (PS) and cardiolipins. (CL), and also recruit complement  
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Figure 7: Functions of natural antibody in homeostasis, by aiding efficient phagocytosis, 
activating complement protein, restrict autoimmunity. Figure reprinted with 
permission182. 
 
components like C1q and MBL to initiate phagocytosis183-185,186. Mice with impaired 
production of IgM not only have problems clearing dead cells, but also suffer from increased 
pathogenic deposition of IgG in tissues 187, 188.  The pictorial representation of different 
functions performed by natural antibodies is demonstrated in the figure 7. 
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1.5.1.3.3 Influencing dendritic cells and regulatory T cells 
The potential role of natural antibodies in improving dendritic cell functions has been 
characterized in mice models. Administration of IgM T15 improved the phagocytotic 
effeciency of these dendritic cells in C1q dependent manner. Moreover, these antibodies, 
prevents dendrtic cells uptake of various TLR ligands (TLR3, TLR4, TLR7 and TLR9) by 
reducing the expression of HLA-DR and CD40 expression168. In vitro addition of IgMs to 
regulatory T cells auguments their share in the T-cell population derived from human plaque 
both in pateints with SLE189. 
1.5.2 Annexin A5 
Annexin-A5 (ANXA5), is a 35.7kDa protein, is a member of the Annexin super-family, that 
binds to phospholipids in a calcium-dependent manner190. Although, originally purified from 
the anti-coagulant fraction of the human umbilical cord artery and placenta191, ANXA5 are 
also produced by endothelial cells and comprises 2% of intracellular protein190. Their 
conserved structure consists of 70 amino acid and a variable N-terminal region, which 
determines the function138. The genes encoding the ANXA5 are present in chromosome 4 at 
4q26-g28192. Although mainly intracellular, they are also found circulating in plasma, urine 
and cerebrospinal fluid at a level of 1-28ng/mL193-195.  These proteins are ubiquitous found in 
fungi and plants and play an essential role in cell signalling and endocytosis190, 196. ANXA5 
has extracellular functions despite being part of intracellular cytosolic protein as reviewed 
in197, 198.  
 Athero-protective properties of AnnexinA5 
The anti-coagulant properties of ANXA5 are well known for their 191. This protein binds with 
high affinity to phosphatidylserine on the surface of apoptotic cells in a calcium dependent 
manner. Phosphatidylserine, is normally found in the inner leaflet of the plasma membrane 
but becomes exposed when the cells are apoptotic or damaged. In fact, ANXA5 is commonly 
used by researchers to identify apoptotic cells and Reutelingsperger, showed ANXA5 can be 
used for detection of vulnerable plaques 199.  
Annexin A5 acts as  two dimensional “band-aid” structure on the surface of endotheial cell 
thereby helping in preventing anti-coagulation 200. Moreover, it is anti-thrombotic by down-
regulating the expression of tissue factor 201. In addition, Annexin A5 inhibit Phopholipase A2 
(PLA2), which plays an important role in synthesizing Platelet Activating factor (PAF) or 
phosphatidylcholine (PtC), thus facilitating chronic immune response that can lead to lesions.  
Evidence suggests that ANXA5 may have a novel function in disease associated with 
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cardiovascular symptoms such as SLE by shielding phospholipids and thus making them 
inaccessible to the coagulation cascade 198. Moreover, ANXA5 binding to OxLDL could 
provide new clue in controlling chronic inflammation 202, 203.  
1.6 SYSTEMIC AUTOIMMUNE DISEASES AND CO-MORBID CVD: 
Each autoimmune disease has its own genetic and pathological abnormalities and consequent 
clinical manifestation. Often, patients with autoimmune diseases, share common symptoms 
with those other having diseases, especially cardiovascular conditions. Increased CVD co-
morbidity is observed in Systemic Lupus Erythmatosus (SLE), Rheumatoid Arthritis(RA), 
Anti-phospholipid syndrome(APS) but such associations has been explored relatively less in 
patients with Systemic Sclerosis(SSc), Sjögren’s syndrome(SjS), Mixed connective Tissue 
Disorder (MCTD), Undefined Connective Tissue Disorder (UCTD). Recent investigations in 
immunological pathway of atherosclerosis, indicates that it shares common pathway with a 
many of autoimmune diseases. Several of the common risk factors, both traditional and non-
traditional which are shown in table 1. The immunopathogenesis of atherosclerosis has led to 
the understanding that activated immune competent cells plays crucial role in all the stages of 
disease. This understanding confirms the shared pathways between different autoimmune 
diseases and atherosclerosis204, 205. Of which, specifically patients with SLE and RA are 
extensively studied for the CVD co-morbidity due to their higher prevalence. 
1.6.1 SLE and CVD 
SLE is a complex systemic autoimmune disease, where various environmental, 
immunological and genetic factors play a vital role in the pathogenesis. One of the hallmark 
features of the SLE is impaired apoptotic clearance, and accumulation of autoantibodies 
against intracellular nuclear components like dsDNA, RO and La, potentially leading to 
immune complex formation, and causing considerable multi- organ damage like nephritis, 
malar rash, arthritis and vascular abnormalities206. This disease affects woman in their 
reproductive age. SLE patients are also characterized by elevated levels of lupus antibodies, 
and approximately 40% of the patients have circulating IgG cardiolipins207. Since this is a 
female centric disease, role of estrogen was also tested in the disease progression. Estrogen, 
helps in survival of autoimmune cells, by facilitating humoral response and B cell survival. 
As discussed above, inefficient clearance of apoptotic cell plays a pivotal role in disease 
initiation due to impaired function of phagocytes and complement functions208, 209.  
CVD co-morbidity among patients with SLE is well understood compared to any other 
autoimmune conditions. Until Urowitz et al.210. described bimodal pattern of mortality in 
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SLE patients and highlighted the CVD, the risk of CVD in SLE patients was under-
appreciated. Accelerated atherosclerosis is the major co-morbid conditions associated with 
SLE, where the risk of stroke and myocardial infarctions are doubled in patients with SLE211. 
 
Table 1: Characteristics of Systemic autoimmune diseases, traditional and non-
traditional risk factors associated with CVD. Table generated based on review by 
Amaya-Amaya and colleagues212. 
Although overall mortality is reduced by approximately 3-20%213, the prevalence of carotid 
plaques increases from 21% to almost 100% from young women to patients above 65 
 
Systemic 
autoimmune 
diseases 
Organs affected Symptoms 
CVD 
comorbidity 
(%) 
Traditional Risk 
factor associated 
with CVD 
Non-Traditional risk 
factor associated 
with CVD 
Systemic Lupus 
Erythmatosus 
(SLE) 
Immune damage to 
different organs (skin, 
kidneys, blood vessel, 
lungs) 
glomerulonephritis, 
Malar rash, 
pulmonary emboli, 
atherosclerosis, 
myocarditis, 
joint stiffness 
The risk for 
CVD is 
doubled in 
patients with 
SLE compared 
to controls 
dyslipidemia, 
male gender, 
metabolic 
syndrome, 
obesity, 
smoking 
advanced age, 
family history of 
CVD, 
polyautoimmunity, 
SLE per se, 
autoantibodies, 
immune cell per se, 
Inflammatory 
markers like CRP 
and ESR, SLE 
associated organ 
damage, Disease 
duration, 
vasculopathy 
Rheumatoid 
Arthritis 
(RA) 
Immune damage joints 
and synovium 
swollen, tender 
joints, stiffness, 
polyarthritis, erosion 
of joint surface 
30-50% 
obesity, 
dyslipidemia, ‘ 
family history of 
CVD, 
hypertension 
HLA-DRB1 SE,  
non -HLA, 
autoantibodies,  
high diseases 
activity, chronic pro-
inflammatory state,  
glucocorticoids, 
Primary 
antiphospholipid 
syndrome 
(PAPs) 
Immune provocation of 
blood clot in arteries 
and veins causing 
complication of 
pregnancy 
deep vein 
thrombosis, 
recurrent 
miscarriage, 
preterm birth, stroke 
1.7-6% and 
can increase to 
14% 
smoking, 
type 2 Diabetes, 
obesity, 
metabolic 
syndrome, 
phospholipid 
autoantibodies 
Sjogren’s 
Syndrome 
(SjS) 
Effects onmoisture 
producing glands 
causing dryness of 
mouth, eyes and skin 
Skin dryness, 
Dry mouth,  
Keratinoconjunctivitis 
sicca 
5-7.5% 
dyslipidemia, 
Type 2 Diabetes, 
advanced age 
autoantibodies, poly-
autoimmunity, 
glucocorticoids, long 
duration of the 
diseases, chronic 
pro-inflammatory 
status, 
glucocorticoids 
Systemic 
Sclerosis 
(SSc) 
 
Autoimmune disease 
of the connective 
tissue especially in the 
skin and small arteries 
and other visceral 
organs like they 
kidneys, heart, lungs 
and gastrointestinal 
tract 
Thick skin, joint pain, 
pulmonary 
hypertension, 
hyperrenemia 
20-30% 
dyslipidemia, 
type 2 Diabetes, 
hypertension, 
hyperhomocystemia 
autoantibodies, 
increased CRP 
Mixed 
Connective 
Tissue  
Disorder 
(MCTD) 
Often shares clinical 
feature with SLE, 
scleroderma, RA and 
myositis 
Joint swelling, 
Raynaud 
phenomenon, 
sclerodactyly 
Poorly defined  hypertension, hyperlipidemia, 
CRP, LDL, 
autoantibody U1-
RNP, 
Undifferentiated 
connective 
Tissue  
Disorder 
        (UCTD) 
Undefined 
dry eyes, dry mouth, 
hair loss, joint 
inflammation, joint 
pain, oral ulcers 
Poorly defined   
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years214. CVD and SLE share some common risk factors as shown in table1 of which 
dyslipidemia and lipid peroxidation are important in-terms of CVD pathogenesis. Both the 
factors could equally contribute to oxidation of LDL eventual clinical consequence of 
atherosclerosis. Antibodies against OxLDL and phospholipids are relevant in this context. In 
consistent with these observation, natural antibody levels, against OxLDL, specifically 
against PC have been much under scrutiny. Various epidemiological observation done by us 
and others have showed, were concordant our observation from patients with CVD139, 158, 167, 
209 i.e., lesser circulating antibodies were associated with IMT progression and disease 
activity in SLE. Patients with SLE are showed decreased binding to the endothelium 
indicating Annexin A5 compete with antiphospholipid antibodies(aPL)201, indicating 
Annexin A5 and aPL compete for same the target. Further insights into other isotypes of PC 
antibodies and mechanism of Annexin A5 are needed for better understanding of the disease 
with respect to phospholipid antigens and their protection against them. 
1.6.2 RA and CVD 
Extra articular manifestations are common among RA patients, virtually affecting multiple 
organs. As mentioned in table 1, patients with RA have increased risk for CVD215 and the life 
expectancy of the patients with CVD risk is reduced by 3-10 years216. Atherosclerosis 
followed by ischemic heart disease are the major cause of death among the patients217 
preceded by vascular damage with dysfunction of endothelium218, 219. Disease modifying 
drugs such as MTX220 and anti-TNF221 and anti-malarial drugs220 were shown to reduce CVD 
risk, by lowing CRP and IL6. Unlike SLE, the role of lipid peroxidation222 is starting to 
emerge recently and prevalence of natural antibodies is not well understood175, 223. And we 
have previously showed anti-TNF and anti-CD20 treatment improves protective natural 
antibody titres in patients with RA169. Altogether, in order to have targeted therapies for 
patients, more studies are to be designed targeting lipid peroxidation and protective factors 
against.  
Although CVD co-morbidity is quite prevalent in other autoimmune diseases like PAPs, SjS 
and SSc, role of small lipid moieties and pathogenesis associated with them is still poorly 
understood. Only large epidemiological studies could give more insight into this situation, to 
develop targeted therapies, for individual patients. 
1.7 THERAPEUTICS IN CVD: 
All these clinical and experimental understanding is aimed for developing targeted therapies 
to CVD patients and autoimmune patients with CVD co-morbidity. Various animal study and 
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large clinical study had led to better understanding of the therapeutic intervention. 
Traditionally stenting and coronary artery bypass surgery were long considered as classical 
intervention employed to treat cardiovascular disease224. Later drugs were designed to 
specifically reduce the deposition of cholesterol and thereby prevent plaque rupture with 
inhibiting HMG-CoA reductase, anti-hypertensives and thrombolytics. Inhibitors of HMG-
CoA reductase marketed as statins are regarded as the successful since they reduce 
cholesterol synthesis by 20-45%. On the other hand, they have side effects affecting the liver 
function of 1-2% of those taking them225, 226. Experimental evidence showed statins could 
reduce activation of T-cells in a microRNA dependent manner227. The hypertensive drug 
amlodipine, showed reduction in cardiovascular events228 but it’s efficacy against IMT is 
limited, as demonstrated by large clinical trials.  
On the other hand, anti-inflammatory therapies had been proposed to modulate and 
ameliorate inflammation either by targeting a molecule or by blocking the mechanism down-
stream. Ongoing clinical trials are testing new or known therapeutics, which were used in 
other chronic diseases such as rheumatoid arthritis (RA) or SLE. These include monoclonal 
antibodies, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-
modifying agents for rheumatoid disease (DMARDs). A retrospective study on the efficacy 
of methotrexate, a folic acid antagonist, proposed reduction in myocardial infarction but not 
associated with stroke229. Addition of methotrexate, downregulates adhesion molecules, 
lipoxygenase, cyclooxygenase and reducing production of cytokine230.  
Apart from this a number inhibitors of lipid mediators are used as potential therapeutic 
intervention for example, leukotrienes inhibitors,231while some other studies pointed out, 
inhibiting cyclooxygenase and phospholipase could improve cardiovascular outcomes232. 
Many animal studies have identified mi-RNAs targets associated with atherosclerosis, based 
on their tissue specific and time dependant patterns of expression233. For example, miR-30, 
miR-92 and miR-145 are potential targets in treating cardiac fibrosis, cardiac apoptosis and 
angiogenesis234. Another approach might be blocking CD40, which was highly effective in 
murine disease models of atherosclerosis but the clinical trial outcome is not yet known235. 
Other researchers have focused on dilmapimod, which inhibits p38MAP kinase, an 
intracellular signalling protein that mediates secretion of inflammatory cytokines. 
Monoclonal antibodies, much appreciated for their specificity, are targeted against 
inflammatory cytokines such as TNF-α (etanercept, adalimumab and infliximab) and IL-1β 
(eg. Canakinumab) 232, though well known for their efficacy in treating RA and other 
autoimmune conditions such as SLE, their therapeutic potential is emerging in patients with 
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CVD. Clinical studies on TNF-α blockades were done in patients with RA with high CVD 
co-morbidity236. The study showed effectiveness of anti-TNF to reduce acute myocardial 
events. In response to high cholesterol levels, macrophages secrete IL-1β237. A phase II 
clinical trial was started with anti- IL-1β monoclonal antibody, in patients with diabetes 
showed reduction in CRP levels238. This lead to ongoing phase III trial, named CANTOS trial 
with 17,200 myocardial infarction patients239, where the end point is reduction of stroke and 
cardiovascular death. Recently, inhibitors of PSCK9 were also effective in lowering 
cholesterol and reducing cardiovascular death in combination with statin treatment240. The 
antibody, also had similar effect in diabetic patients, where they reduced cardiovascular risk 
and incident diabetes241. About 10 monoclonal antibodies were approved by the FDA are 
listed below. 
          
             Table 2: Monoclonal antibodies against cardiovascular in clinical trials.  
Though antibodies against phospholipids has been studied for athero-protective and 
homeostatic function, thus far only monoclonal “E06” was developed and studied exclusively 
in animal models. Development of human monoclonals will be a valuable tool as these 
antibodies will be helpful in assessing the functions in homeostasis and other pathogenic 
conditions, especially, atherosclerosis and autoimmune conditions. 
Despite the profound knowledge on pathology, associated risk factors and targeted therapies, 
cardiovascular diseases, still remains leading cause of death in the world, and also among 
patients with CVD co-morbidity in autoimmune diseases. This emphasizes the necessity for 
 
Type Name Target Status 
Human Alirocumab Blocks PCSK9 Phase III to IV 
 Canakinumab Neutralized IL1beta Phase I to III 
 Evinacumab Blocks Angptl3, lower LDL Phase I 
 Evolocumab Blocks PCSK9 and lowers LDL 
Phase I to 
III 
 Inclacumab Blocks inflammatory cell extravasation Phase II 
Humanized Eculizumab C5 complement inhibitor Phase IV 
 Tadocizumab Blocking interaction with fibrinogen and fibronectin Phase II 
 Tocilzumab Block IL6 receptor Phase II 
 TS23 Inhibits alpha-2 anti-plasmin Phase I 
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finding other novel risk factors, with the help of powerful epidemiological studies and 
subsequent experimental testing. The current knowledge on different risk factors and even the 
success of treatments was derived from such studies using robust statistical associations. Such 
testing might lead to improved therapeutic intervention and precise medicine specific for 
patients in CVD and autoimmune conditions leading to better quality of life and eventual 
reduction in death.  
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2 AIMS OF THE THESIS 
The overall aim of the thesis is to understand the prevalence and function of protective factors 
against oxidation induced phospholipids, in inflammatory and autoimmune conditions and to 
elucidate their protective role using human cell culture system.  
The specific aims include: 
Study I: To investigate binding and anti-inflammatory property of Annexin A5 against 
oxidized cardiolipin. 
Study II: To study prevalence of anti-MDA IgMs in 60-year Old CVD patients. 
Study III: To study the prevalence of anti-PC and anti-MDA IgMs among different Systemic 
autoimmune patients(SADs). 
Study IV: To study the role of anti-PC IgG1 in SLE pateints and functions of in-house 
generated anti-PC IgG1s in human cell culture system. 
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3 METHODOLOGICAL CONSIDERATION 
In order to answer the specific research question, this section summarizes the human 
materials used to explore biomarkers related to cardiovascular diseases and methods 
employed to understand potential properties of Annexin A5 and monoclonal antibodies. 
3.1 PATIENT COHORT 
A cohort, in the medical field, is typically defined as a group of individuals with specific 
characteristics, recruited to determine either new incidence, cause or prognosis of a 
diseases242. In order to elucidate, the prevalence of natural antibodies and to evaluate 
relationship between the antibody circulating levels and outcomes patients with CVD and 
autoimmune diseases, we employed cohort based approach to answer our research question. 
We typically employed three different cohorts, as illustrated in the figure 8 below. The 
patient’s serum samples were collected, and other demographic and disease related 
observation were recorded during initial recruitment are used for association analysis.  
Although we found the prevalence and association with the disease activity, we did not find 
any causal relationship using this type study.  
 
 Figure 8: Different cohort used employed in the thesis. 
3.1.1 60-Year-Old Cohort (Study II) 
This is typical longitudinal cohort, where between July 1997 and June 1998, every third man 
and woman from Stockholm county who turned 60 was invited to participate in the 
cardiovascular health screening and 4232 (2039 men and 2193 women) agreed. 
approximately 78% response rate was recorded. The patients were followed up to identify 
cases of CVD, National Death Registry up until December 2003, and National In-Hospital 
Registry, until 2005 was examined resulting in 209 cases. Three random controls for every 
PresentPast Future
Cross	sectional	Study
PRECISESADS,	Study	 III
Longitudinal	 cohort
60-year-old	cohort,	Study	 II
Case	control	study
SLEVIC	cohort,	Study	IV
Start	of	investigation
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case were matched for age and gender, the characteristics are presented below. The level of 
anti-MDA IgM in blood samples from all of these subjects were determined. 
3.1.2 PRECISESADS Cohort (Study III) 
PRECISESADS (Precision medicine strategies for Systemic autoimmune diseases) is a cross-
sectional cohort, collected from December 2014 to October 2017, with participants from 
twelve different European countries. The 2656 participants were recruited that includes: 377 
with rheumatoid arthritis (RA), 470 with systemic lupus erythematosus (SLE), 402 with 
systemic sclerosis (SSc), 385 with Sjögren’s syndrome (SjS), 99 cases with mixed connective 
tissue disorder (MCTD), 106 with primary antiphospholipid antibody (PAP), 166 
undifferentiated connective tissue disorder (UCTD) patients and 651 healthy controls (HC). 
Ethical permission was obtained from the countries, where patients and controls were 
recruited. The characteristics of the controls and patients with their established clinical score 
are presented in the table below. 
3.1.3 The SLEVIC Cohort (Study IV) 
The Systemic Lupus Erythmatosus Vascular Investigation cohort (SLEVIC) included patients 
who demonstrated clinical manifestation of CVD, and age and gender matched controls 
receiving care at Karolinska University Hospital, Stockholm, Sweden. All of these patients 
fulfilled revised American College of Rheumatology (ACR) for SLE. This study was 
approved by the Regional Ethical Review Board at Karolinska Institutet, Stockholm, Sweden 
and was performed in accordance with the Declaration of Helsinki. All subjects provided 
their informed consent before entering the study. 
3.2 CLINICAL SCORING 
3.2.1 CVD co-morbidity definition (Study III) 
We estimated the cardiovascular (CV) score based on the presence of cardiovascular-related 
symptoms including: Arrythmia, Coronary artery disease, Hypertension, Pericarditis, 
Pulmonary arterial hypertension by right-heart catheterization, Pulmonary hypertension on 
Echo, Valve lesions, Arterial/Venous thrombosis, Gangrene of the fingers, History of 
Raynaud's phenomenon, History of recurrent miscarriage or pregnancy complications and 
Ischemic digital ulcers/Pitting scars. The present study did not differentiate the cardiovascular 
symptoms but categorized them as “2” if the cardiovascular symptoms are present, “1” if the 
cardiovascular scores were present in the past and “0”, when cardiovascular symptoms are 
absent. 
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3.2.2 Carotid Ultrasound (Study IV) 
The measurement of intima media thickness (IMT), is considered as a global score for 
atherosclerotic measurement. The right and left carotid arteries were examined with the B 
mode ultrasonography. The mean of the maximum intima thickness is determined in the far 
wall, as the distance between the echo from the leading edge of the lumen intima and lumen 
adventitia both in the common carotid and bifurcations. When the intima media thickening is 
greater than “1”, it is defined as plaque. The vulnerable/echolucent plaque is graded between 
1 and 4, when “1” is echolucent, “2” predominantly echolucent “3” predominantly echogenic, 
and “4” echogenic. 
3.3 ENZYME LINKED IMMUNOSORBENT ASSAY 
3.3.1 Biomarker measurement in cohorts (Study II, III and IV) 
The circulating levels of these natural antibodies (IgMs and IgGs) among different patients 
and control groups, was measured using ELISA. For this purpose, we developed an ELISA 
procedure which was optimized for each individual experiment. PC-BSA or MDA-HSA 
(10µg/mL) was coated on 96 well NUNC immune plates and incubated overnight at 4°C. 
Thereafter, the plates were washed and blocked with 2% BSA for at least one hour after 
which the samples and standards were diluted with 0.2% BSA and added at 100µl for each 
well for two hours. The plates were washed and added with biotin/alkaline-phosphatase 
conjugated IgM/IgG secondary antibody at specified concentration for 2 hours. The samples 
were further incubated with Streptavidin (for biotin conjugated IgM, IgG1 or IgG2) or pnPP 
(for alkaline phosphatase conjugated IgM) 20 min and 75 min respectively. The reaction was 
stopped with 1N H2SO4/3M NaOH and the absorption were read at 450nm/405nm 
respectively. The values presented are relative units (RU/mL) depending on the OD values of 
the standards used in the cohort. This technique has a lot of advantages, that includes: high 
sensitivity, specificity and throughput and consuming lesser time, where we can use samples 
frozen for certain period of time. However, in this in-house technique, we did not find the 
concentration of the circulating levels in absolute values, rather quantitated them relative to 
the standard used, which makes it difficult to compare with other similar studies. 
3.3.2 Monoclonal binding and competition assays (Study IV) 
The microtiter plates were coated with different antigens in their oxidized or native states to 
understand the binding of in-house produced antibodies. The antigens were coated at specific 
concentration and antibodies were serially dilutes and added at different concentration from 
20µg to 0.16µg per milliliter and studied for the binding effect. For the competition assay, the 
 32 
antibodies were incubated with different concentration of the competitor and the competition 
was assessed in percentage by calculating the difference in the OD values in the presence or 
absence of competitor. 
3.4 AFFINITY PURIFICATION OF NATURAL ANTIBODIES (STUDY II, III) 
The anti-PC/MDA IgMs and their non-binding counterparts, were extracted from human IgM 
(Sigma Aldrich). Enrichment of anti-PC and anti-MDA IgM was achieved with Hi-trap NHS 
column (GE healthcare, Sweden). Briefly, MDA-human serum albumin and PC-bovine 
serum albumin (1mg/mL) was coupled to this column after extensive equilibration with 
solution of high and low pH, was then loaded with human IgM and incubated for several 
hours. Unbound IgMs were eluted as flow-through (FT). After continuous washing with 
buffer, anti-PC and anti-MDA IgMs were eluted using glycine-HCl elution buffer. The 
obtained antibodies and their flow-through counterpart were desalted using PD-10 desalting 
column (GE Healthcare, Sweden). Finally, the enriched antibody solution was passed through 
a 0.22um filter and stored at -20°C until future use.  
3.5 MONOCLONAL PRODUCTION AND GENE SEQUENCING (STUDY IV) 
Monoclonals antibodies are directed against one specific epitope are now widely used to treat 
many inflammatory and autoimmune diseases. Monoclonal antibodies (mAbs) against 
phosphorylcholine were isolated from single PC-reactive B-cells from healthy human donors. 
The corresponding genetic sequences were determined and c-DNAs (complementary DNA) 
synthesized were cloned into expression vectors coding for human Igγ (Ig gamma heavy 
chain), Igλ (lambda light chain) or Igκ (kappa light chain). The antibodies were produced by 
co-transfecting into exponentially growing human embryonic kidney (HEK) cells. After 
seven days of cultures, the proteins(antibodies) were purified in Protein G chromatography 
column. The antibody protein purity and the expression of heavy and light chains were 
confirmed by SDS-PAGE. Advantages of this method includes its specificity to one 
particular antigen and easy production. Also, these are fully human antibodies, which can be 
employed directly to the human cells. However, one limitation here is we were not able to 
assess the systemic effect of these antibody in in-vitro cell culture models, for example 
immune complex formation.  
The antibody affinity to PC-hapten was measured by Surface plasmon resonance on Biacore 
X-100(GE healthcare, Uppsala, Sweden).  For every B cells on the 96 well plates, matching 
IgH and Igκ/Igλ were obtained were sequences at the genes encoding them determined 
employing the Eurofins MGW operon. The sequence was analysed for somatic hyper 
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mutation and CDR3 variability using IMGT tools and the sequence were compared using 
multiple sequence alignment tool (MUSCLE) to understand the similarity and differences 
between the generated antibodies.  
3.6 DE-NOVO SEQUENCING USING MASS SPECTROMETRY (STUDY II, III, 
AND IV) 
The extracted IgMs were subjected to proteomics analysis to characterize the peptide 
sequences of anti-PC IgM, anti-MDA IgM and monoclonal antibodies. The extracted IgMs 
were reduced using dithiotreitol and subjected to alkylation at 37°C. The mass spectrometry 
was based on principle of liquid chromatography. The samples were injected into the nano-
liquid chromatography system. The mass spectra were obtained in the range of m/z 300-70 
with a resolution of 12,0000. The raw data were processed using spotlight approach which is 
combination of de-novo sequence and existing sequence. The abundance of peptides were 
normalized.  
3.7 CELL CULTURE 
3.7.1 Primary cell culture 
Buffy coats were purchased from Karolinska University Hospital. cultivation of neutrophils 
(Study I), buffy coats were subjected to dextran sedimentation followed by gradient 
centrifugation on lymphoprep (Axis-Shield PoC AS, Oslo, Norway). The isolated neutrophils 
are used for calcium mobilization and LTB4 production study. In case of Macrophages 
(Study I and IV), isolated PBMCs were made positive selection for CD14 positive beads 
(Milteyni Biotech). The CD14+ cells were differentiated into M2 macrophages with MCSF 
(50ng/mL) stimulation for 4 days. The macrophages were subjected to study the 
improvement in the phagocytosis efficiency in the presence or absence of IgG1 anti-PC 
antibodies. Regulatory T cells (Study III), were generated by pre-coating with anti-CD3 
antibody (10 µg/mL) (eBioscience), together with soluble anti-CD28 antibody (1 µg/mL) 
(eBioscience), IL-2 (10 ng/mL), TGF-β1 (10 ng/mL) (Immuno Tools), in culture medium for 
six days and Tregs were stimulated with phorbol myristate acetate (50 ng/mL) and Ionomycin 
(1 µg/mL) for 5 hours on the harvest day.  
3.7.2 Cell Lines 
 HUVECS (Study I) 
Human Umbilical Vein endothelial cells (HUVECs) were purchased from Life technologies. 
and were subjected to stimulation with Oxidized Cardiolipin(OxCL) to study the pro-
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inflammatory effects exerted by OxCL, in activating the endothelial cells, by studying 
increase in surface expression markers VCAM and ICAM. 
 THP1 cells (Study IV) 
THP1 cells were purchased from ATCC. The cells were differentiated into macrophage like 
using PMA (Phorbol 12-myristate 13-acetate) for 72 hours and stimulated with different 
concentration of LPS to study the effect of anti-inflammatory property of IgG1 anti-PC. 
 Jurkat cells (Study IV) 
Jurkat cells were also purchased from ATTC. Jurkat cells were subjected to apoptosis, to 
study antibody binding, complement deposition and efficiency of phagocytosis uptake by the 
macrophages. 
3.8 PHAGOCYTOSIS ASSAY (STUDY IV) 
Buffy coats were purchased from Karolinska University Hospital. PBMCs were isolated 
followed by positive selection for CD14 (Milteyni Biotech). The CD14+ cells were 
differentiated into M2 macrophages with MCSF(50ng/mL) stimulation for 4 days. For the 
phagocytosis assay, apoptotic jurkat cells were incubated with antibodies, with or without 
serum for 1 hour. Prior to apoptosis induction, Jurkat T-cells were subjected to TAMRA 
staining (microscopic examination) or CFSE (FACS analysis) for 20 minutes at serum free 
conditions before. Antibodies tagged apoptotic cells were incubated with macrophages for 1 
hour at 10% IgG deficient serum. The cells were washed and fixed with paraformaldehyde, 
prior to microscopic examination. The cells counterstained with DAPI. Images were recorded 
using fluorescent microscope. Phagocytosis efficiency was determined by number of 
macrophages that uptake apoptotic jurkat to the total number of macrophages using flourscent 
microscopy. 
3.9 GENE EXPRESSION ANALYSIS (STUDY I) 
To study gene expression of COX-2 and 5-LOX, RNA was extracted using QIAGEN mini 
kit. The extracted RNA was converted to cDNA using reverse transcriptase kit. The gene 
expression of COX-2 and 5-LOX was studied using designed primers. The obtained values 
were normalized against b-actin and presented as relative measures.  
3.10 FLOW CYTOMETRY (STUDY I AND IV): 
Flow cytometry is a robust tool where it finds its application in medical field, especially in 
single cells to study expression of surface markers, intracellular markers, complement 
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deposition, to mention some. Cultivated human macrophages, HUVECS, Jurkat, regulatory T 
cells were subjected to flow cytometric analysis to study the expression of surface markers 
and phagocytosis efficiency of macrophages. 
3.11 STATISTICAL ANALYSIS (ALL STUDIES): 
A pairwise t-test was employed for all clinical studies. A binary logistic regression was used 
for clinical associations such plaque development and SLE disease index (Study II and IV). 
For assessing the difference in antibody level among different autoimmune patients, using 2-
tailed t-test along with non-parametric epps-singleton test. Spearman Rank correlation was 
employed for the correlation between antibody level and cardiovascular score (CV) (Study 
III). Student t-test was employed for all the experimental analysis (Study I and IV). For the 
peptide characterization, we employed both univariate and multivariate approach for principle 
component analysis and orthogonal projection to latent structures discriminate analysis using 
Simca 14.0, Umetrics (Study II and III). Statistical test where p<0.05 is considered 
significant. 
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4 RESULTS AND DISCUSSION 
4.1 Oxidized but not native Cardiolipins is pro-inflammatory  
The double bond of linoleic acid moiety in cardiolipin is prone to oxidation243, which occurs 
during apoptosis or oxidative stress, releasing cytochrome-c through the action of cardiolipin 
specific peroxidase244, 245. Although oxidized cardiolipins were found in both  atherosclerotic 
lesion and apoptotic cells246, their immunogenic properties were not clarified in this context. 
First, we wanted to determine whether this phospholipid in its oxidized form promotes the 
production of inflammatory mediators, such as leukotrienes, due to their potential 
inflammatory role in atherosclerosis, stroke and myocardial infarction231. Leukotrienes 
mediates inflammation through autocrine and paracrine signalling, particularly by secreting 
chemokines to attract neutrophils to site of injury and facilitates cytokine production by 
immune competent cells247. Accordingly, this study was designed to elucidate some 
important aspects of inflammation induced by oxidized cardiolipin. 
Since atherosclerotic lesion are abundantly filled with monocytes/macrophages and recent 
evidence suggested neutrophils deposition, we wanted to know if addition of OxCL to 
immune competent cells like macrophages and neutrophils stimulates the production of 
LTB4. Indeed, increased leukotriene secretion by both cell types in a dose dependent manner, 
induced by OxCL was dependent on calcium. In fact, neutrophils were more potent than 
macrophages (Fig 9). The intracellular calcium mobilization as augmented by OxCL, was 
measured fluorimetrically with FURA-2A. This response by macrophages is particularly 
interesting because of their significance in the pathogenesis of atherosclerosis248-250. Calcium 
mobilization plays an integral role in many physiological processes, especially in connection 
with neurotransmission, contraction of muscle fibres, but excessive mobilization might have 
significant role in apoptosis and necrosis (Reviewed by Pinton)251 which could possibly have 
detrimental role in atherosclerosis. Calcium flux is also known to affect mitochondrial 
membrane251.  
 
  37 
       
Figure 9: Leukotriene production by human monocyte derived macrophages and 
neutrophils upon oxidized cardiolipin stimulation and subsequent abrogation by 
Annexin A5. 
Addition of OxCL to human macrophages or neutrophils, increased 5-LOX expression but 
did not enhance the expression of COX-2, which is consistent with the production of 
leukotrienes by 5-LOX. It is well known that arachidonic acid is the end product of linoleic 
acid degradation, which could be due to oxidation or enzymatic reaction. 5-LOX, also known 
as arachidonate 5-lipoxygenase, a lipoxygenase, converts essential fatty acid such as 
arachidonic acid into leukotrienes252, a potent inflammatory mediator, in a calcium dependent 
manner253 and is known to play a significant role in plaque rupture. 5-LOX was also found to 
be positively associated with atherosclerosis severity250.  
4.2 Annexin A5 binds to OxCL 
Annexin A5, being a cytosolic protein, known for its binding to phospholipids. To determine 
whether the inflammatory burden caused by oxidized cardiolipin could be abrogated by 
Annexin-A5 we first looked for potential binding of Annexin A5 by classical ELISA assay. 
We demonstrated that Annexin A5 binds more strongly to OxCL than to native (CL) or 
reduced cardiolipin (R-CL) as shown in figure 10. The minimal oxidation when CL is 
exposed to air that occur could explain this binding to the cardiolipin not oxidizing 
intentionally. 
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Figure 10: Annexin A5 demonstrates higher binding efficiency to oxidized cardiolipin 
than to native or reduced cardiolipin. 
Next, we wanted to elucidate if Annexin A5 has any anti-inflammatory role. We found that 
Annexin A5 abrogated and in fact totally eliminated the increase in leukotriene production by 
macrophage and neutrophils caused by OxCL and calcium mobilization. OxCL, also 
enhances VCAM-1 and ICAM-1 at the cell surface, a hallmark of atherogenesis that allows 
monocyte and lymphocytes to bind to the endothelial cells and this validates the OxCL could 
also be potential candidate in vascular inflammation. Once again, this effect was abrogated by 
Annexin-A5 addition, primarily by preventing OxCL from binding to endothelial cells.   
There are two possible mechanisms, for oxidation of cardiolipin: one, through oxidation of 
LDL itself, as cardiolipins are part of LDL, and another, by exposure of mitochondrial 
membrane in apoptotic and necrotic cells accumulated in the lesion. In both the cases, 
oxidative mechanism converts cardiolipin to oxidative cardiolipin which could lead to this 
downstream inflammatory function as we demonstrate in this study, thereby contributing to 
pathogenesis. It should also be noted that binding of Annexin A5 and CRP to OxLDL was 
demonstrated earlier, although they had different binding sites202. CRP is known to recognize 
PC moiety both in OxLDL and apoptotic cells101, so Annexin A5 might bind to OxLDL 
plausibly recognizing OxCL. 
Though we addressed an important question in this study, we did not demonstrate the clues 
concerning the exact site at which Annexin A5 binds to OxCL. In fact, we did not 
demonstrate the competition of Annexin A5 to other inflammatory phospholipids such as 
phosphatidylserine or OxCL was not done here or their binding to the atherosclerotic plaque 
was demonstrated. Although we proposed LTB4 as one inflammatory mediators secreted by 
immune competent cells, we did not address other possible inflammatory mediators such as 
platelet activating factor or lyso-phosphatidylcholine which are also relevant in the 
pathogenesis.  
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4.3 Anti-MDA IgM and the risk for CVD 
Previous findings indicate a negative correlation between serum levels of anti-PC IgMs and 
the risk for CVD among 60-year-old patients172. Here, we investigated the same potential 
correlation for anti-MDA IgM in the same set of patient and compared these to matched 
control. The prevalence of smoking, BMI, glucose and hypertension, the classical risk factors, 
were higher among the cases. Moreover, patients with CVD have lower amount of circulating 
IgMs against malondialdehyde (MDA-HSA) than matched controls.  
In the cohort, we identified with patients with cases with one of the following outcomes: 77 
with myocardial infarction (MI), 85 patients with angina pectoris and 49 with ischemic 
stroke. When considering MI and stroke, the odds of these patients developing CVD were 
twice as high for controls in the lowest tertile, below 10th percentile, [OR(CI), 2.16(1.31–
3.55)], although the odds were much improved after adjusting for smoking, hypertension, 
BMI and Type 2 diabetes. The associations were similar, when the MI and angina were 
treated as outcome.  
Further, when stratified for gender, men showed higher risk, compared to women. For the 
men, the odds ratio was as high as 2.62 and 2.73 for MI/stroke and MI/angina respectively, in 
the lowest tertile, (below 10th percentile) and the risk increased, when adjusted for 
confounders. Although, antibodies were associated with a protective effect above 66th 
percentile, the odds reduced to 0.54 and even more so above the 90th percentile (0.34). With 
better effect on men these finding indicate that IgM against malondialdehyde protect against 
CVD in 60-year old patients. Although this biomarker was strongly associated with men, no 
such association was observed for woman. One reason for this bias could be lesser female 
subjects in the entire study.  
4.4 Polyclonal anti-MDA IgMs differs from other IgMs 
The non-MDA binding IgMs (flow- through, FT) contained a larger number of peptides than 
MDA IgMs indicating that the latter are more conserved. Anti-MDA IgMs are produced by 
B1-cells, which produce natural antibodies and these antibodies are presumed to exhibit little 
or no somatic hyper-mutation. To our knowledge, the peptide sequences of these IgMs have 
not been documented before. Of the 2429 peptides identified, 1061 were identified through 
de novo sequencing and 738 showed distinct sequence homology. Only 20% of the peptides 
present in the FT were also present in the anti-MDA IgM.  
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Figure 11: Difference between anti-MDA IgM and control FT in the variable region of 
heavy and light chain. 
More specifically, there was no difference with respect to the heavy chain, but peptides were 
present in the kappa chain of anti-MDA IgM whereas relatively higher abundance of lambda 
chains was observed in the non-anti-MDA IgM. Thus, it was apparent that these antibodies 
were more homogenous compared to the FT, confirming these antibodies must not have 
undergone mutation over time as they recognise conserved sequence in the antigen.  
Next, we wanted to understand how these antibodies, recognize the antigen, we examined the 
complementary determining region (CDR3 and CDR2) and also Framework (FR) region, as 
shown in figure 11. Compared to the FT controls the sequence 
ENDNKFSFDYWGQGTLVTVSSASTK and FSFDYWGQGTLVTVSSASTK were 
enriched in CDR3 and the sequence ASTLQSGVPSR and LLLYAASTLQSGVPSR were 
enriched in CDR2 region MDA IgM. It should be noted that these IgMs are polyclonal and 
are germ-line encoded.  
The CDR3 region of the antibody can be regarded as fingerprint of an antibody. Given its 
poly-specificity nature, and previous finding suggesting their T –cell dependency135, 136, we 
were curious to investigate the variability in the CDR3 region of the heavy and light chain. 
Our data suggested that the antibodies were homogenous compared to the controls. This is 
indicative from the previous studies on mice models, where, monoclonals, E014147 and 
NA17147 against malondialdehyde modified LDL, generated from germ-free mice did not 
show variability in the antigen binding region and were much comparable to T15 idiotype. 
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On the whole, through this study we characterized human natural occurring antibodies 
against malondialdehyde modified HSA.  
4.5 Antibodies against PC and MDA are different among different rheumatic diseases 
Although the elevated risk among patients with low-level of anti-PC and/or anti-MDA IgMs 
(study II) have been studied extensively in connection with cardiovascular disease patients 
the putative roles of these antibodies in other systemic inflammatory autoimmune diseases 
had not been documented. A present novel finding, among patients with different diseases of 
this sort, serum levels of anti-PC IgM were reduced in those with MCTD vs controls, RU/mL 
(61.5 ± 38.7 vs 73.9 ± 34.3), with no difference in the anti-MDA level (62.9 ± 33.3 vs 69.3 ± 
34.2) as shown in figure 12. 
In agreement with our previous observations, a clear reduction in IgMs against PC was 
observed patients with SLE compared to the controls (68.3 ± 36.5 vs 73.9 ± 34.3). Although 
lower levels were also common among those with other diseases like systemic sclerosis 
(SSc), these values did not differ significantly from those of controls. In contrast, elevated 
levels of both antibodies were detected in patients with rheumatoid arthritis (RA) and primary 
phospholipid syndrome (PAPs). Also reported previously175, but only the level of anti-MDA 
IgG was associated with Disease activity score(DAS28).  
Given the ubiquitous nature of the phospholipids, their relevance seemed to gain importance 
not just in lipid driven diseases like atherosclerosis but also, many other inflammatory 
condition, where oxidative bursts are one among the causative. Autoimmune diseases are 
characterized by elevated levels of pathogenic IgG autoantibodies directed toward altered 
self-antigens. Here we have elucidated the circulating levels of protective autoantibodies, also 
directed towards altered self-antigens in patients with different autoimmune diseases. The 
most interesting case among these group of patients was MCTD, due to their rare occurrence 
and degree of complexity and sharing clinical manifestation with other diseases. In fact, 
patients with MCTD were also presented with severe cardiovascular co-morbidity, which 
could partly explain why specifically anti-PC but not anti-MDA is not illustrated in this 
disease. Patients with MCTD present with features such as arthritis, swelling of the hands and 
fingers, thickening of the skin, Raynaud’s syndrome and pleuritis to mention a few. Some 
population based studies have pointed out the prevalence rate as 3.8-6.5 per million per 
year254, 255, in certain population with strong association to human leukocyte antigen256. 
Association of anti-phospholipid antibodies are studied in relevance to pathogenesis257, 
although only antibodies against U1 small  nuclear ribonucleoprotein (U1 snRNP) has been 
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strongly associated the diseases, not to be confused with levels in patients with SLE, where 
the levels are much higher in latter compared to patients with MCTD258. Due to it’s rarity and 
complexity, the need for other novel risk markers was absolute necessary. Prevalence of low 
anti-PC IgM in this cohort is quite novel. Investigation concerning mechanisms linking anti-
PC IgM and disease pathogenesis has to be studied.    
                     
                    
Figure 12: IgM antibodies against PC and MDA exhibited different profile in different 
rheumatic diseases. 
Though PC and MDA are known to be present as dominant epitope in apoptotic cells and 
OxLDL, the circulation levels of antibodies against them are quite different, in fact level of 
MDA IgM does not differ much from the controls, except for PAPs and RA. Taken together, 
we can see both these antibodies were uniformly distributed, in fact in higher levels in serum 
of the patients PAPs and RA, which is consistent with previous findings by Grönwall and 
colleagues175. Although both IgM and IgG antibodies against PC and MDA were elevated in 
RA patients, only MDA IgGs were associated with the disease activity score. Therefore, this 
elevated level in the RA does not always account for pathogenicity, suggesting some alternate 
functions associated with this prevalence. Similarly, patients with PAPs have higher 
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circulating levels of these antibodies. In general, antibodies against phospholipids are 
elevated in this set-up. The most studied ant-phospholipid antibodies are anti-cardiolipins in a 
β2-glycoprotein dependent or independent manner.  
Although the cross-sectional design of the study could be one limitation to understand the 
causation effect of these antibodies, it was interesting to note how these antibodies are 
presented differently in different autoimmune diseases. Correlation analysis with other 
pathogenic autoantibodies and genetic factors, example. HLA DR, specifically comparing B1 
cell distribution among patient and control (probably achieved by constructing nest-case-
control) deserves further study. 
4.6 Antibody levels and CVD comorbidity 
The protective role of antibodies against phosphorylcholine and malondialdehyde is well 
understood in connection with cardiovascular outcomes, as is the fact that patients with 
autoimmune diseases often exhibit a variety of co-morbid conditions, especially 
cardiovascular symptoms. In our cohort, patients with different cardiovascular and other 
comorbid conditions were identified and stratified on the basis of CVD co-morbidity. It is to 
be noted the patients in different group exhibited different cardiovascular scores. Patients 
with systemic sclerosis had more cardiovascular co-morbidity, followed by MCTD, as 
illustrated in figure 13. Although patients with PAPs and RA had significantly lower 
cardiovascular score compared to others. 
In the patients with MCTD and co-morbidity, there was a negative correlation between CVD 
scores and the levels of both antibodies, (anti-PC IgM: rho=-0.37, p=0.002 and anti-MDA 
IgM: rho=-0.32, p=0.01). We in our lab have demonstrated negative correlation of antibodies 
with CVD155, 162, 172, finding in patients with MCTD are novel. Previously, increased levels of 
HSP60, were also linked to cardiovascular co-morbidity259. Similar to our previous findings, 
SLE patients also showed negative correlations, although that with anti-PC IgM was 
statistically significance. The results for patients with UCTD were similar. Interestingly, 
patients with rheumatoid arthritis also exhibited the same tendency, although their IgM levels 
were higher than those of controls, (anti-PC IgM: rho=-0.16, p=0.007 and anti-MDA IgM: 
rho=-0.12, p=0.04). Among patients with Sjögren’s syndrome the statistical significance was 
borderline, whereas patients with systemic sclerosis or primary phospholipid syndrome 
demonstrated no correlation. Although patients with systemic sclerosis showed the highest 
cardiovascular scores, the levels of antibodies did not differ significant. Unlike our other 
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studies, cardiovascular score included in this study, consists of broad spectrum of outcomes. 
Therefore, this limits our conclusion, to any particular co-morbid condition.  
 
  
Figure 13: Correlation analysis of anti-PC and anti-MDA IgMs with different 
cardiovascular co-morbidity in systemic autoimmune diseases.   
4.7 Antibodies influence regulatory T-cells in different fashions 
Dysfunction of regulatory T cells are not only important in regulating homeostasis and self-
tolerance but are believed to be vital cause in many autoimmune diseases such as RA, SLE. 
Here we found that in-vitro stimulation of anti-PC but not anti-MDA IgM increases the 
number of T-reg cell frequency. Charolette and colleagues, in their review described 
potential challenges and controversies of T regs associated with autoimmune diseases260. In 
fact, anti-PC IgMs enhanced this number even among regulatory T cell from SLE patients 
and atherosclerotic plaque175. Known for their suppressive functions a steady decline in 
regulatory T-cells occurs in patients with active autoimmune diseases such as SLE261, 262 and 
rheumatoid arthritis263 and even in animal models of atherosclerosis. Recently, T-regs were 
found to improve macrophage efferocytosis function in an experimental mice model264. 
Another study in mice showed that adoptive transfer of T-regs reduced macrophage and T-
cell accumulation in atherosclerotic lesion265. An analysis of T-reg population in humans with 
coronary artery diseases and acute coronary syndrome revealed fewer in circulation266, 267. 
Depressed level of these cells are also common among MCTD268, sjogren’s syndrome269 and 
systemic sclerosis270. 
The results show one of the important immunomodulatory function imposed by anti-PC IgM 
on regulatory T cells. In terms of atherosclerosis, increasing T reg population could probably 
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decrease foam cell formation and increase in anti-inflammatory macrophage population. In 
case of patients with RA, anti-TNF treatment enhance the T-reg population271 and we have 
shown anti-TNF treatment improves serum levels of anti-PC IgM level in patients with 
RA169. 
4.8 The peptide sequence of antibodies to phosphorylcholine and malondialdehyde 
are different 
Natural antibodies were characterized in the 1970’s and 1980’s, but mostly in mice272. To 
look for difference in the antibody peptide sequence of anti-PC and anti-MDA antibodies 
using de-novo sequencing followed by univariate and multivariate analysis. To our 
knowledge, this has not been done before. In general, both of these antibodies had a lower 
number of lambda regions than their flow-through counterparts. The CDR3 antigen 
recognition sequence in the heavy variable ENDNKFSFDYWGQGTLVTVSSASTK and 
FSFDYWGQTLVTVSSASTK, were present in both, whereas the sequence 
EESFWGQGTLVTVSSASTK was unique in anti-PC IgM, as demonstrated in table 3. 
Similarly, there were four peptide sequence that were specific for anti-PC IgM but not anti-
MDA IgM nor their flow-through counterparts. Interestingly, in the light chain, the sequence 
of the CDR2 region of the variable kappa chain was similar to PC and MDA IgM.  
The multivariate OPLS- DA analysis showed distinct separation of flow-through from anti-
MDA and anti-PC IgMs along the x-axis and separating anti-PC and anti-MDA IgM along y-
axis. Therefore, through this analysis we identified eight peptide segments that are common 
between antibodies and the flow-through, eight peptide segments specific for anti-PC IgMs 
and three peptide segments specific for anti-MDA IgMs. This shows the both commonality 
between anti-PC and anti-MDA IgM, which could probably explain its redundant function 
with the uptake of apoptotic cells and other similar homeostatic function. Whereas, the 
unique sequence explains the functional differences related to identifying peptide sequences 
specific for them, which in-turn determines their fate. 
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          Table 3: Antibody peptide characterization of anti-PC and anti-MDA IgM. 
4.9 Serum levels of anti-PC IgG1 are negatively associated with clinical outcome 
patients with SLE 
Serum levels of both anti-PC IgG1 and IgG2 were higher among patients with SLE than 
controls (IgG1: 68±4.4 vs 55.8±2.7, p=0.02) and (IgG2: 101.5±16.8 vs 114.28±12.2, p=0.53). 
Our patients exhibited vascular inflammation and more CVD than the control. In patients 
with plaque, the levels of these antibodies were even lower in SLE patients, although only 
significantly so in the case of anti-PC IgG1 (55.2±3.4 vs 78.2±7.4p=0.006) alone reached 
significance. This difference was even more pronounced when comparing vulnerable 
plaques, especially in left carotid.  
Next, we wanted to determine whether these antibody levels were correlated with clinical 
outcome with respect to SLE, specifically with SLEDAI, SLAM and SLICC activity and 
vascular complications eg: plaque and CVD complications. The level of anti-PC IgG1s were 
divided into quartiles, and the odds ratio and confidence intervals for different clinical 
consequences calculated. Overall, this level was negatively associated with the clinical 
complications. The negative correlation of antibodies for determining plaque vulnerability 
was already shown using correlation analysis167. Similarly, in hypertensive subjects, Igg1 was 
shown to be associated with IMT porgession164. Here, we showed he IgG1 anti-PC but not 
IgG2 were negatively correlated with plaque vulnerability, just like anti-PC IgM. Of course, 
this did not reach significance, which could be probably due to higher variation among the 
levels of patients. Similarly, we observed anti-PC IgG1s correlated with increased 
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atherosclerosis measures and cardiovascular events, below 25th percentile [OR, CI; 2.71, 
(1.03-7-09)], and even stronger at 10th percentile, [OR, CI; 2.71, (1.03-17.4)]. Similarly, the 
anti-PC IgMs were negatively correlated with organ damage index SLICC and diseases 
activity score SLEDAI, but not SLAM. Since these antibodies change with time, we did not 
adjust the outcome with confounders. Of the three, SLEDIA was correlated the most, below 
10th percentile, OR, CI [5.1, (1.3-20)]. And these antibodies were protective by at least 20-
30% with these scores.  
Impaired clearance of apoptotic cell, is the characteristics of patients with SLE and leads to 
the release of potential danger signals, including nuclear antigens, against which pathogenic 
IgG autoantibodies are produced. Furthermore, cardiovascular diseases are one of the major 
co-morbid conditions among patients with a 50% higher prevalence than in controls. 
Atherosclerotic plaque contains a necrotic core with foam cells loaded with lipids and other 
cellular debris. This study gave an insight into the direct correlation of the antibodies with 
CVD related outcomes and SLE related outcomes indicating, not just IgM but also IgGs 
especially IgG1 could play potential role in SLE prognosis. 
4.10 Dynamism among clonally selected antibodies 
Since under such circumstances efficient clearance of apoptotic cells is absolutely necessary, 
we generated fully human IgG1s against phosphorylcholine to understand their function in 
connection with this process. Phosphorylcholine, is a dominant epitope of both apoptotic cells 
and oxidized LDL. Three monoclonal antibodies, A01, D05 and E01 each with different 
binding affinities were chosen; the corresponding gene sequences were analysed with IgBlast 
tool, to determine whether the antibodies were germ-line encoded or had undergone any 
somatic hyper-mutation and the amino acid sequences was compared using Multiple 
Sequence Alignment Tool (MUSCLE). The was a major difference in the amino acid 
sequence of the complementary determining region (CDR3), where the monoclonal 
antibodies A01 and D05 were similar, but E01 lacked peptides in the concerned region. 
Binding of these antibodies to phosphorylcholine and other lipids in both the native and 
oxidized states was examined by ELISA. As expected all in a similar manner bound to 
phosphorylcholine linked to BSA (PC-BSA). However, D05 demonstrated highest binding 
capacity to oxidized LDL, followed by A01 and E01. Moreover, D05 bound strongly to 
POVPC, whereas E01 and A01 did not bind at all.  
On the other hand, none of these antibodies bound to native protein, LDL, PtC or BSA, 
demonstrates their specificity for oxidized phospholipids. In the case of phosphorylcholine, a 
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component of the Streptococcus pneumoniae. E01 exhibited the highest binding affinity, 
followed by D05 and then A01. Unlike in eukaryote systems, where it is bound to protein or 
lipid, PC in Streptococcus is bound to a carbohydrate. One plausible reason for this 
differential recognition is the difference in the amino acid sequence of the CDR3 region, in 
the heavy chain. We, in our previous study showed the difference in recognition of 
phosphorylcholine by IgG1 and IgG2 subtypes164, where IgG1 were shown to be important in 
recognizing both phosphorylcholine and p-nitrophenyl-phosphorylcholine, NPPC (a PC 
hapten), whereas IgG2 only recognized NPPC, binding to the phenyl ring, indicating their 
crucial difference in recognizing PC haptens. Therefore, this identification lead to the division 
of PC specific antibody into two groups: group1 consisting of anti-PC IgMs, Igg1s and IgA, 
performing similar function and group II consists of IgG2 helps in identification of 
carbohydrate associated PC antigens. This was validated, using PC-IgG2, were elevated in 
patients with periodontitis suffered from increased risk for CVD. Overall, this interesting 
difference might provide a valuable tool to studying not only anti-PC antibodies that bind 
endogenous antigens but also fatal streptococcus and developed as vaccine for future. 
4.11 Anti-PC IgG1 improves the efficiency of phagocytosis by macrophages 
Since PC exposed at the surface of the apoptotic cells, we next incubated the antibodies with 
apoptotic cells. The antibodies A01 and D05, but not E01 bound to apoptotic and necrotic but 
not viable cells. Isotype controls did not bind to the apoptotic cells, as was confirmed by 
FACS. In the presence of D05, the efficiency of the uptake of apoptotic jurkat cells by 
macrophages increased from 19% to 31%, also rising to the 23% in the presence of A01 but 
E01 or isotype controls. As expected, since none of the antibodies bound to live cells, they 
did not facilitate uptake of such cells. Even in serum free conditions, the D05 mAb exerted a 
similar significant effect indicating lack of serum dependency.  
In the presence of serum deposition of complement protein C1q on apoptotic cells increased 
from 0.072% to 4.72% and antibody did not alter this deposition, indicating that uptake of 
apoptotic cell may involve Fc-gamma receptor. In contrast, complement protein C3b did not 
deposit either in the absence or presence of antibody. Again, the difference in binding 
specificity, could reflect whether PC is bound to protein or carbohydrate with difference in 
sequence from E01 antibody determining the antibody binding to the lipid. The elegant role 
of anti-PC IgMs in apoptotic cell uptake were clearly demonstrated in a number of mice and 
human studies135, 147, 168, 183. 
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Figure 14: Monoclonal D05 (anti-PC IgG1) improves phagocytosis efficiency of 
macrophages. 
As already described anti-PC IgMs and IgG1s are termed as group I antibodies, that could 
help in important homeostatic function such as removing apoptotic cells, binding to oxidized 
LDL, and subsequent inhibiting the uptake by macrophages172. The proposed role of anti-PC 
clone D05 in improving apoptotic cell uptake, thereby reducing further inflammation is 
shown in figure 15. 
 
   
 
Figure 15: Proposed role of monoclonal D05 increasing apoptotic uptake by phagocytes 
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5 GENERAL DISCUSSION 
The protective properties of natural antibodies especially, anti-PC IgM is well documented in 
the field of cardiovascular research69. The function of antibodies/factors against other relevant 
phospholipids are emerging. Biochemical characterization of the OxLDL lead to discovery of 
new phospholipid epitopes that are immunologically relevant. In fact, these oxidized 
phospholipids are the major targets of the innate immune system and has been a major topic 
of interest in the field of atherosclerosis, due to their protective property71. Persistent 
inflammation and increased production of ROS, shifts the paradigm towards autoimmune 
state. At the same time, the phospholipids are ubiquitous, and peroxidation can affect any cell 
type, thus could potentially lead to increased exposure of phospholipids, marking the 
beginning of inflammation. Unlike other pathogenic immune cells, B-cells or their products 
(antibodies), have not been sharply linked to pathogenic outcomes in CVD. Despite many 
traditional risk, the necessity for the search of other novel risk factors has never declined.  
Oxidized phospholipids: a link between autoimmune disease and CVD? 
Years ago, our group proposed the plausible role of oxidized phospholipids in patients with 
disease such as SLE, RA and anti-phospholipid syndrome (APS)273. Aforementioned, about 
30-50% of autoantibodies against phospholipids are found circulating in patients with SLE 
and about one third develop APS with characteristic enhanced level of autoantibodies against 
cardiolipins (aCL), and anti- β2 glycoprotein (β2GPI) antibodies and lupus anti-coagulants. A 
number of studies pointed out accelerated atherosclerosis in both patients with PAPs as well 
as SLE, with increase in IMT as a classical sign. Some other studies showed interaction of 
OxLDL with β2GPI to form immune complex (IC), suggesting a plausible reason for 
vascular pathogenesis, that are inflicted in the case of SLE, APS and SSc274. In this thesis, we 
have discussed about prevalence of two antibodies that are epitopes of OxLDL. Although we 
focused on immunologically relevant epitopes of OxLDL, understanding the prevalence of 
these antibodies could shed light in phospholipid related immune activation and their possible 
role in rare chronic conditions. RA, though not a vascular related disease, dyslipidemia is 
associated with early stages of the disease. OxLDL seems to create pro-oxidative state in 
patients with RA, leading to further clinical consequences. In one of our studies, we showed, 
anti-PC IgM increased anti-TNF therapy, indicating dampening the inflammation alters lipid 
profile and this study also gives clue regarding reverting the protective natural antibodies 
with the help of anti-inflammatory therapy. 
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In study III we showed levels of natural antibodies and the associated CVD co-morbidity 
varied among patients with different rheumatic diseases. With the existing knowledge on 
OxLDL and cardiolipins in some autoimmune conditions, we wanted to extend our 
knowledge on PC and MDA to other conditions and specifically rare diseases, included 
within this broader group. We were able to confirm our finding with previous known data 
with respect to SLE, and find novel association with MCTD. Further investigation into other 
isotypes of antibodies and association with other classical autoantibodies could give insight in 
to possible clue to underlying disease mechanisms. 
Natural Antibodies and Annexin, a possible therapy in CVD and autoimmune 
condition? 
Given the clinical significance of these antibodies against OxLDL, especially small hapten 
like PC was a major interest in the animal models of atherosclerosis275. The authors showed 
active immunization with PC-KLH reduced plaque size and increased antibody titres (IgG 
and IgM)275. Years ago, immunizing of ApoE KO mice with OxLDL, in the neonatal stage, 
has showed reduction in atherosclerosis through deletion of reactive T cells276. Due to 
molecular mimicry between pneumococcus capsule and OxLDL, researchers even showed 
reduction in atherosclerotic lesion upon pneumococcus vaccination149. Experimental evidence 
using E06 (classical mouse T15 antibody) have shown to increase apoptotic cell uptake in 
mice models as well as reduce inflammatory arthritis149. A number of in-vitro experiment 
from our lab have pinpointed the reduction uptake of OxLDL149 and increase regulatory T 
cell population189. Recently immunization with MDA-LDL also showed to reduce plaque size 
in atherosclerotic prone mice277. However, it is still hard to translate the finding to humans. 
Recently we developed fully human monoclonal antibodies (Study IV), against 
phosphorylcholine resulting in improved phagocytosis efficiency and dampened LPS induced 
inflammation. Both the property could be relevant in SLE and atherosclerosis where prompt 
removal of apoptotic cell is crucial. Immunization studies could possibly explain the systemic 
effect of the antibody in humans. 
Similar to natural antibodies, Annexin A5 functions has been much studied in diseases such 
as SLE and anti-phospholipid syndrome. Annexin A5 has lower binding capacity to the 
endothelium in the patients with SLE201. A passive immunization could also be potential 
therapy in such patients, where Annexin A5 could potentially initiate antithrombotic 
events201. In the animal models Annexin A5 prevents vascular injury by accumulating and 
preventing the generation of thrombin. It is also proposed that Annexin A5 forms band-aid on 
the endothelial cells thus preventing them from rupture. Recently potential anti-inflammatory 
 52 
role was proposed, where Annexin A5 ameliorate leukotriene production203, which is of 
immense interest as they can dampen subsequent clinical adversity.  
Considering potential benefits of the natural antibodies and Annexin A5, active or passive 
immunization would prove beneficial to patients with CVD and autoimmune diseases 
especially SLE or MCTD with CVD co-morbidity.  
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6 CONCLUDING REMARKS 
In the present thesis, I document associations between circulating levels of IgM antibodies 
against three products of oxidization i.e., phosphorylcholine, malondialdehyde, and oxidized 
cardiolipin and protection against cardiovascular and systemic autoimmune diseases in 
humans. This protective role of natural anti-PC IgMs155, 156, 162, 164, 278, 279, as well as Annexin 
A5197, 198, 201 against CVD has also been observed previously.  Here, we demonstrate a novel 
anti-inflammatory role played by Annexin A5 against oxidized cardiolipins and report on the 
prevalence of natural IgM antibodies in patients with cardiovascular and rare autoimmune 
diseases and employing pre-clinical studies to develop them into therapeutics for future.  
In our first investigation, we found that oxidized cardiolipin exerts a pro-inflammatory effect 
on human macrophages and neutrophils in a calcium-dependent manner. In addition, we 
showed that Annexin-A5 binds to OxCL, but not native or reduced cardiolipin. OxCL 
stimulated the secretion of leukotrienes by macrophages and neutrophils in a manner 
dependent on 5-LOX and Annexin A5 abrogated this effect. Overall, Annexin A5 neutralized 
the pro-inflammatory effects of OxCL by binding directly to this epitope. 
In our second set of experiments, we found associations between low levels of circulating 
IgMs against malondialdehyde in patients and increased cardiovascular risk, whereas higher 
levels appeared to be protective. In agreement with our previous observations155, the levels of 
natural anti-MDA IgM were lower in patients than in age- and gender-matched controls, 
especially in the case of the men. Proteomics analysis of the polyclonal anti-MDA IgM 
revealed less sequence variability in the CDR3 region, which presumably contributes to their 
specificity.  
In our third study, we extended these findings to systemic autoimmune diseases, 
demonstrating differences in circulating levels of anti-PC and anti-MDA IgM among patients 
with various autoimmune diseases. Furthermore, low levels of anti-PC, but not anti-MDA 
IgM were associated with diseases such as SLE and, in particular, with the rare and poorly 
defined autoimmune disease MCTD. When the patients were stratified on the basis of their 
cardiovascular scores, this negative association in the case of MCTD was even much 
stronger. Interestingly, higher levels of these antibodies were common among patients with 
RA. Peptide analysis of these antibodies showed certain similarities and differences that 
might contribute to their differences in recognition and thus involvement in various diseases.   
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Finally, we demonstrated that circulating levels of anti-PC IgG1, but not IgG2 were 
negatively associated with plaque vulnerability, history of CVD, and disease activity in 
patients with SLE. Our monoclonal antibodies targeted against phosphorylcholine improved 
the efficiency of phagocytosis by macrophages in a fashion dependent on Fc, also reducing 
inflammation. This indicates one possible mechanism by which anti-PC IgG1 could protect 
patients with SLE, since impaired clearance of apoptotic cells is a hallmark of this 
pathogenesis.  
Our future efforts will be designed to understand potential associations between these and 
other pathogenic autoantibodies, as well as the mechanisms by which they regulate or 
modulate homeostasis and disease. Moreover, we will examine the effects of our monoclonal 
anti-PC antibodies in animal models of systemic autoimmune diseases. In addition, human 
monoclonal antibodies against other products of oxidation, including malondialdehyde and 
oxidized cardiolipins, will be developed and employed to elucidate the roles of these products 
in connection with oxidative pathogenesis. These belong to the repertoire of natural 
antibodies, the development of which from birth to adulthood in humans is still poorly 
understood. Mechanistic and omics-based approaches will be employed to monitor this 
development, which is important in understanding their involvement in pathological 
conditions. We hope that one day these protective factors can both provide valuable 
diagnostic markers and lead to the development of vaccines that can improve treatment of or 
perhaps even help prevent the development of inflammatory, cardiovascular and autoimmune 
diseases. 
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